0001503274-24-000027 | 10-Q/A | XBRL Viewer

Fair value of financial instruments - Changes in Carrying Value (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying value of the Company's Level 3 financial assets	$ 292,890	$ 309,162
Nonrecurring \| Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying value of the Company's Level 3 financial assets	$ 800	$ 800

Allowance for Credit Losses (Tables)

3 Months Ended

Mar. 31, 2024

Allowance for Credit Loss [Abstract]

Schedule of the allowance for credit losses

The change in the allowance for expected credit losses on accounts receivable is summarized as follows (in thousands):


	2024		2023
Balance at December 31 of prior year	$	454	$	118
Provision for expected credit losses	176		178
Write-offs and recoveries collected	(103)		(74)
Balance at March 31	$	527	$	222

Commitments and Contingencies - Undiscounted future lease payments for non-cancelable operating leases (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Maturity of lease liabilities
2024 (remainder)	$ 5,340
2025	7,254
2026	7,408
2027	7,641
2028	7,880
2029	8,126
Thereafter	7,612
Total lease payments	51,261
Less: imputed interest	10,811
Total operating lease liabilities	$ 40,450

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accrued Expenses and Other Current Liabilities
Accrued professional services	$ 1,947	$ 1,596
Accrued royalties	1,631	1,689
Accrued tax liabilities	1,446	822
Other accrued expenses	1,958	1,948
Total accrued expenses and other current liabilities	$ 6,982	$ 6,055

Income Taxes (As Restated) (Details) (10Q)	3 Months Ended
Income Taxes (As Restated) (Details) (10Q)	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate reconciliation, percent	1.60%	2.00%

Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2024

Investments, Debt and Equity Securities [Abstract]

Debt Securities, Available-for-Sale

The amortized cost, gross unrealized gains, gross unrealized losses, and fair value of the Company’s marketable securities by major security type were as follows (in thousands):


	As of March 31, 2024
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper	$	42,947	$	—	$	(40)	$	42,907
U.S. Treasuries	73,033		—		(23)		73,010
U.S. Government agency bonds	78,389		10		(149)		78,250
Corporate bonds	79,012		55		(136)		78,931
Total marketable securities	$	273,381	$	65	$	(348)	$	273,098

Marketable securities are recorded in the following Consolidated Balance Sheets captions:
Cash and cash equivalents							$	16,458
Marketable securities							256,640
Total marketable securities							$	273,098


	As of December 31, 2023
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper	$	53,482	$	23	$	(12)	$	53,493
U.S. Treasuries	4,896		1		—		4,897
U.S. Government agency bonds	28,366		39		(7)		28,398
Corporate bonds	66,726		289		(8)		67,007
Total marketable securities	$	153,470	$	352	$	(27)	$	153,795

Marketable securities are recorded in the following Consolidated Balance Sheets captions:
Cash and cash equivalents							$	6,893
Marketable securities							146,902
Total marketable securities							$	153,795

Unrealized Gain (Loss) on Investments

The following tables show the fair value and gross unrealized losses of the Company’s available-for-sale securities, with unrealized losses that are not deemed to be other-than-temporary aggregated by major security type and length of time that the individual securities have been in a continuous unrealized loss position (in thousands):


	Less Than 12 Months
As of March 31, 2024	Fair Value		Unrealized Losses
Commercial paper	$	38,497	$	(40)
U.S. Treasuries	73,010		(23)
U.S. Government agency bonds	69,825		(149)
Corporate bonds	48,629		(136)
Total	$	229,961	$	(348)


	Less Than 12 Months
As of December 31, 2023	Fair Value		Unrealized Losses
Commercial paper	$	32,137	$	(12)
U.S. Government agency bonds	15,861		(7)
Corporate bonds	8,367		(8)
Total	$	56,365	$	(27)

Investments Classified by Contractual Maturity Date

The following table summarizes the contractual maturities of the Company’s marketable securities (in thousands):


	As of March 31, 2024				As of December 31, 2023
	Amortized Cost		Fair Value		Amortized Cost		Fair Value
Due within one year	$	209,554	$	209,378	$	95,188	$	95,232
Due in one to two years	63,827		63,720		58,282		58,563
Total	$	273,381	$	273,098	$	153,470	$	153,795

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

+ Details

Revenue Recognition - Grant revenue (Details) - USD ($) $ in Thousands			3 Months Ended
	Sep. 21, 2022	Mar. 24, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Total revenues			$ 32,066	$ 28,456
Research and development			6,742	4,987
Deferred revenue			(472)	(2,041)
Commitments and contingencies (Note 15)
ADDF
Contract value		$ 2,300	2,300
National Institutes of Health
Contract value	$ 1,700
Grants Received			800
Grant revenue
Total revenues			274	$ 222
Grant revenue \| ADDF
Deferred revenue			$ 1,000

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Summary of restricted stock units activity


	Number of options	Weighted-average exercise price per share		Weighted-average remaining contractual life (in years)	Aggregate intrinsic value
Outstanding at December 31, 2023	2,774	$	19.62	7.9	$	26,941
Granted	1,179	22.74
Exercised	(104)	12.34
Forfeited/expired	(181)	20.24
Outstanding at March 31, 2024	3,668	$	20.80	8.3	$	17,741
Exercisable at March 31, 2024	1,297	$	22.24	6.6	$	7,615
Vested and expected to vest at March 31, 2024	3,668	$	20.80	8.3	$	17,741

Restricted Stock Units

Restricted stock unit (“RSU”) activity for the three months ended March 31, 2024 is presented below (in thousands, except per share amounts):


	Number of shares	Weighted-average grant date fair value per share
Unvested at December 31, 2023	1,328	$	17.87
Granted	446	24.40
Vested	(197)	17.57
Forfeited	(96)	20.52
Unvested at March 31, 2024	1,481	$	19.71

Summary of share-based compensation expense for all stock awards

Stock-based compensation expense was recorded in the following categories on the Consolidated Statements of Operations (in thousands):


	Three Months Ended March 31,
	2024		2023
			(As Restated)
Cost of product revenue	$	281	$	197
Cost of service and other revenue	308		350
Research and development	543		379
Selling, general and administrative	4,133		3,017
Total stock-based compensation expense	$	5,265	$	3,943

Income Taxes (As Restated)	3 Months Ended
Income Taxes (As Restated)	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes (As Restated)	Note 12. Income Taxes (As Restated) The Company’s effective tax rates were (1.6)% and (2.0)% for the three months ended March 31, 2024 and 2023, respectively. The income tax provision and effective tax rate is driven primarily by a valuation allowance in the United States, partially offset by income taxes in foreign jurisdictions. The Company maintains a valuation allowance on the majority of its deferred tax assets, and it has concluded that it is more likely than not that the deferred assets will not be utilized.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Significant Accounting Policies - Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Cash and Cash equivalents
Cash and cash equivalents	$ 45,281	$ 174,422	$ 329,354
Restricted cash	2,605		2,598
Cash, cash equivalents, and restricted cash	$ 47,886	$ 177,026	$ 331,952	$ 341,337

Restatement of Financial Statements - Statement Of Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Reclassification [Line Items]
Net loss	$ (11,163)	$ (7,274)
Other comprehensive loss, net of tax:
Unrealized gains on marketable securities	(607)	0
Foreign currency translation adjustment	(674)	42
Total other comprehensive loss	(1,281)	42
Comprehensive loss	(12,444)	(7,232)
As Previously Reported
Reclassification [Line Items]
Net loss	(10,072)	(6,103)
Other comprehensive loss, net of tax:
Unrealized gains on marketable securities	(607)	0
Foreign currency translation adjustment	(674)	42
Total other comprehensive loss	(1,281)	42
Comprehensive loss	(11,353)	(6,061)
Adjustments
Reclassification [Line Items]
Net loss	(1,091)	(1,171)
Other comprehensive loss, net of tax:
Unrealized gains on marketable securities	0	0
Foreign currency translation adjustment	0	0
Total other comprehensive loss	0	0
Comprehensive loss	$ (1,091)	$ (1,171)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Organization and Nature of Business	3 Months Ended
Organization and Nature of Business	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	QUANTERIX CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Note 2. Organization and Nature of Business Quanterix is a life sciences company that has developed next generation, ultra-sensitive digital immunoassay platforms that advance life sciences research and diagnostics. The Company’s platforms are based on its proprietary digital “Simoa” detection technology and enable customers to reliably detect protein biomarkers in ultra-low concentrations in blood, serum, and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. The ability of the Company’s Simoa platforms to detect proteins in the femtomolar range is enabling the development of novel therapies and diagnostics and has the potential to facilitate a paradigm shift in healthcare from an emphasis on treatment to a focus on earlier detection, monitoring, prognosis, and, ultimately, prevention. The Company also provides contract research services for customers and Laboratory Developed Test (“LDT”) services through its CLIA-certified Accelerator Laboratory (the “Accelerator Laboratory”). The Accelerator Laboratory provides customers with access to its Simoa technology and its Lucent Diagnostics clinical testing services (launched in July 2023) and supports multiple projects and services, including sample testing, homebrew assay development, custom assay development, and blood-based biomarker testing. To date, the Company has completed over 2,300 projects for more than 480 customers from all over the world using its Simoa platforms.

Commitments and contingencies (Tables)

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum lease payments

The undiscounted future lease payments for non-cancelable operating leases were as follows (in thousands):


Maturity of lease liabilities	As of March 31, 2024
2024 (remainder)	$	5,340
2025	7,254
2026	7,408
2027	7,641
2028	7,880
2029	8,126
Thereafter	7,612
Total lease payments	51,261
Less: imputed interest	10,811
Total operating lease liabilities	$	40,450

Revenue Recognition

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Revenue and Related Matters

Note 4. Revenue and Related Matters

Revenue from Contracts with Customers

The Company’s customers primarily consist of entities engaged in life sciences research that pursue the discovery and development of new drugs for a variety of neurologic, oncologic, cardiovascular, infectious disease, and other protein biomarkers associated with diseases. The Company’s customer base includes pharmaceutical, biotechnology, contract research organizations, academic, and government institutions.

Disaggregated Revenue

When disaggregating revenue, the Company considers all of the economic factors that may affect its revenues. The following table disaggregates the Company’s revenue from contracts with customers by geography, based on the location products and services are consumed, and revenue type (in thousands):


	Three Months Ended March 31, 2024								Three Months Ended March 31, 2023
	North America		EMEA		Asia Pacific		Total		North America		EMEA		Asia Pacific		Total
	(As Restated)		(As Restated)		(As Restated)				(As Restated)		(As Restated)		(As Restated)		(As Restated)
Product revenue:
Instruments	$	408	$	1,269	$	869	$	2,546	$	2,144	$	1,981	$	1,135	$	5,260
Consumable and other products	10,297		4,299		2,528		17,124		7,497		4,971		1,632		14,100
Total	$	10,705	$	5,568	$	3,397	$	19,670	$	9,641	$	6,952	$	2,767	$	19,360

Service revenue:
Service-type warranties	$	1,637	$	852	$	194	$	2,683	$	1,517	$	675	$	133	$	2,325
Research services	5,762		2,802		127		8,691		5,190		234		115		5,539
Other services	318		248		27		593		381		257		4		642
Total	$	7,717	$	3,902	$	348	$	11,967	$	7,088	$	1,166	$	252	$	8,506

Collaboration and license revenue:
Total	$	155	$	—	$	—	$	155	$	368	$	—	$	—	$	368

For the three months ended March 31, 2024, no customer accounted for more than 10% of the Company’s total revenues and for the three months ended March 31, 2023, one customer accounted for more than 10% of the Company’s total revenues. At March 31, 2024 and December 31, 2023, one customer accounted for more than 10% of the Company’s gross accounts receivable.

Eli Lilly and Company Service Revenue Agreements

On February 25, 2022, the Company entered into a Master Collaboration Agreement with Eli Lilly and Company (“Lilly”) establishing a framework for future projects focused on the development of Simoa immunoassays (the “Lilly Collaboration Agreement”). The Company also entered into a statement of work under the Lilly Collaboration Agreement to perform assay research and development services within the field of Alzheimer’s disease. Under the statement of work, the Company receives $1.5 million per calendar quarter, which began in the first quarter of 2022. The statement of work automatically renews on a quarterly basis until Lilly provides a termination notice in accordance with the terms of the Lilly Collaboration Agreement. As of March 31, 2024, the Lilly Collaboration Agreement and the statement of work were still in effect.

Concurrent with the execution of the Lilly Collaboration Agreement, the Company entered into a Technology License Agreement (the “Lilly License”) under which Lilly granted the Company a non-exclusive license to Lilly’s proprietary p-Tau 217 antibody technology for use in research use only products and services and future in vitro diagnostics (“IVD”) applications within the field of Alzheimer’s disease. In consideration of the Lilly License, the Company paid an upfront fee, is required to make milestone payments based on the achievement of predetermined regulatory and commercial events, and will pay royalties on net sales of licensed products.

The Company recognized $1.5 million of revenue from the Lilly Collaboration Agreement during the three months ended March 31, 2024 and 2023.

Contract Assets

There were no contract assets as of March 31, 2024 or December 31, 2023.

Deferred Revenue

During the three months ended March 31, 2024 and 2023, the Company recognized $2.7 million and $2.4 million of revenue, respectively, related to its deferred revenue balance at January 1 of each such period.

Remaining Performance Obligations

As of March 31, 2024, the aggregate amount of transaction prices allocated to performance obligations that were not yet satisfied, or were partially satisfied, was $11.2 million. Of this amount, $10.2 million is expected to be recognized as revenue in the next 12 months, with the remainder expected to be recognized thereafter. The $11.2 million primarily consists of amounts billed for undelivered services related to initial and extended service-type warranties and research services.

Costs to Obtain a Contract

Changes in costs to obtain a contract were as follows (in thousands):


	2024		2023
Balance at December 31 of prior year	$	288	$	377
Capitalization of costs to obtain a contract	97		197
Recognition of costs to obtain a contract	(95)		(191)
Balance at March 31	$	290	$	383

The Company evaluates potential impairment of these amounts at each balance sheet date, and no related impairments were recorded during the three months ended March 31, 2024 and 2023.

Grant Revenue

All of the Company's grant revenue is generated within North America.

NIH Grant

On September 21, 2022, the Company and the National Institutes of Health (the “NIH”), an agency of the U.S. Department of Health and Human Services, entered into a contract (the “NIH Grant”) with a total award value of $1.7 million. The NIH granted the Company funding in support of the development of certain point-of-care diagnostic technologies through collaborative efforts. Grant funding is to be used solely for activities related to the point-of-care diagnostic device development project and the contract period runs through August 2025. Receipt of the award value occurs throughout the term of the contract period and after the Company submits for reimbursement of activities related to the grant. As of March 31, 2024, the Company had received $0.8 million of the total award value.

During the three months ended March 31, 2024 and 2023, grant revenue recognized and research and development expenses incurred were not material.

ADDF Grant

On March 24, 2022, the Company and the Alzheimer’s Drug Discovery Foundation (the “ADDF”) entered into a contract (the “ADDF Grant”) with a total funding value of $2.3 million. The ADDF is a charitable venture philanthropy entity that granted the Company funding in support of certain activities for the development of an IVD test for early detection of Alzheimer's disease. The ADDF Grant restricts the Company’s use of the granted funds solely for activities related to the Company’s Alzheimer’s diagnostic test development project and the contract period runs through June 2024. Receipt of the contract funding was subject to achievement of pre-defined milestones, and as of December 31, 2023, the Company had received the total funding value of $2.3 million.

During the three months ended March 31, 2024 and 2023 grant revenue recognized and research and development expenses incurred were not material. As of March 31, 2024, the Company had $1.0 million of deferred revenue related to the ADDF Grant.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

Leases (Tables)

3 Months Ended

Mar. 31, 2024

Lessee Disclosure [Abstract]

Schedule of undiscounted future lease payments for non-cancelable operating leases

The undiscounted future lease payments for non-cancelable operating leases were as follows (in thousands):


Maturity of lease liabilities	As of March 31, 2024
2024 (remainder)	$	5,340
2025	7,254
2026	7,408
2027	7,641
2028	7,880
2029	8,126
Thereafter	7,612
Total lease payments	51,261
Less: imputed interest	10,811
Total operating lease liabilities	$	40,450

Fair value of financial instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash equivalents - money market funds	$ 36,250	$ 162,260
Marketable securities	256,640	146,902
Total Financial Assets	292,890	309,162
Money market funds
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash equivalents - money market funds	19,792	155,367
Commercial paper
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash equivalents - money market funds		1,996
Marketable securities	42,907	51,498
U.S. Treasuries
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash equivalents - money market funds	16,458	4,897
Marketable securities	56,552
U.S. Government agencies
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Marketable securities	78,250	28,398
Corporate bonds
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Marketable securities	78,931	67,006
Quoted prices in active markets (Level 1)
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash equivalents - money market funds	19,792	155,367
Total Financial Assets	19,792	155,367
Quoted prices in active markets (Level 1) \| Money market funds
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash equivalents - money market funds	19,792	155,367
Significant other observable inputs (Level 2)
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash equivalents - money market funds	16,458	6,893
Marketable securities	256,640	146,902
Total Financial Assets	273,098	153,795
Significant other observable inputs (Level 2) \| Commercial paper
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash equivalents - money market funds		1,996
Marketable securities	42,907	51,498
Significant other observable inputs (Level 2) \| U.S. Treasuries
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash equivalents - money market funds	16,458	4,897
Marketable securities	56,552
Significant other observable inputs (Level 2) \| U.S. Government agencies
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Marketable securities	78,250	28,398
Significant other observable inputs (Level 2) \| Corporate bonds
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Marketable securities	$ 78,931	$ 67,006

Restatement of Financial Statements - Statement Of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 32,066	$ 28,456
Costs of goods sold and services:
Total costs of goods sold and services	13,518	12,463
Gross profit	18,548	15,993
Operating expenses:
Research and development	6,742	4,987
Selling, general and administrative	26,039	20,784
Other lease costs	924	800
Total operating expenses	33,705	26,571
Loss from operations	(15,157)	(10,578)
Interest income (expense), net	3,948	3,449
Other income (expense), net	226	(5)
Loss before income taxes	(10,983)	(7,134)
Income tax (expense) benefit	(180)	(140)
Net loss	$ (11,163)	$ (7,274)
Net loss per common share, basic (in dollars per share)	$ (0.29)	$ (0.19)
Net loss per common share, diluted (in dollars per share)	$ (0.29)	$ (0.19)
Weighted-average common shares outstanding, basic (in shares)	38,126,000	37,327,000
Weighted-average common shares outstanding, diluted (in shares)	38,126,000	37,327,000
Product revenue
Revenues:
Total revenues	$ 19,670	$ 19,360
Costs of goods sold and services:
Total costs of goods sold and services	8,237	7,879
Service revenue
Revenues:
Total revenues	11,967	8,506
Costs of goods sold and services:
Total costs of goods sold and services	5,281	4,584
Collaboration and license revenue
Revenues:
Total revenues	155	368
Grant revenue
Revenues:
Total revenues	274	222
As Previously Reported
Revenues:
Total revenues	32,066	28,456
Costs of goods sold and services:
Total costs of goods sold and services	12,440	11,530
Gross profit	19,626	16,926
Operating expenses:
Research and development	6,675	4,720
Selling, general and administrative	25,993	20,850
Other lease costs	924	776
Total operating expenses	33,592	26,346
Loss from operations	(13,966)	(9,420)
Interest income (expense), net	3,948	3,449
Other income (expense), net	206	8
Loss before income taxes	(9,812)	(5,963)
Income tax (expense) benefit	(260)	(140)
Net loss	$ (10,072)	$ (6,103)
Net loss per common share, basic (in dollars per share)	$ (0.26)	$ (0.16)
Net loss per common share, diluted (in dollars per share)	$ (0.26)	$ (0.16)
Weighted-average common shares outstanding, basic (in shares)	38,126,000	37,327,000
Weighted-average common shares outstanding, diluted (in shares)	38,126,000	37,327,000
As Previously Reported \| Product revenue
Revenues:
Total revenues	$ 19,670	$ 19,287
Costs of goods sold and services:
Total costs of goods sold and services	7,145	7,033
As Previously Reported \| Service revenue
Revenues:
Total revenues	11,967	8,579
Costs of goods sold and services:
Total costs of goods sold and services	5,295	4,497
As Previously Reported \| Collaboration and license revenue
Revenues:
Total revenues	155	368
As Previously Reported \| Grant revenue
Revenues:
Total revenues	274	222
Adjustments
Revenues:
Total revenues	0	0
Costs of goods sold and services:
Total costs of goods sold and services	1,078	933
Gross profit	(1,078)	(933)
Operating expenses:
Research and development	67	267
Selling, general and administrative	46	(66)
Other lease costs	0	24
Total operating expenses	113	225
Loss from operations	(1,191)	(1,158)
Interest income (expense), net	0	0
Other income (expense), net	20	(13)
Loss before income taxes	(1,171)	(1,171)
Income tax (expense) benefit	80	0
Net loss	$ (1,091)	$ (1,171)
Net loss per common share, basic (in dollars per share)	$ (0.03)	$ (0.03)
Net loss per common share, diluted (in dollars per share)	$ (0.03)	$ (0.03)
Weighted-average common shares outstanding, basic (in shares)	0	0
Weighted-average common shares outstanding, diluted (in shares)	0	0
Adjustments \| Product revenue
Revenues:
Total revenues	$ 0	$ 73
Costs of goods sold and services:
Total costs of goods sold and services	1,092	846
Adjustments \| Service revenue
Revenues:
Total revenues	0	(73)
Costs of goods sold and services:
Total costs of goods sold and services	(14)	87
Adjustments \| Collaboration and license revenue
Revenues:
Total revenues	0	0
Adjustments \| Grant revenue
Revenues:
Total revenues	$ 0	$ 0

Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Marketable Securities [Line Items]
Amortized cost	$ 273,381	$ 153,470
Unrealized Gains	65	352
Unrealized Losses	(348)	(27)
Fair Value	273,098	153,795
Marketable securities	256,640	146,902
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months	229,961	56,365
Unrealized Loses	(348)	(27)
Amortized cost due within one year	209,554	95,188
Fair value due within one year	209,378	95,232
Amortized cost due in one to two years	63,827	58,282
Fair value due in one to two years	63,720	58,563
Accrued interest receivable	1,200	1,000
Commercial paper
Marketable Securities [Line Items]
Amortized cost	42,947		$ 53,482
Unrealized Gains			23
Unrealized Losses	(40)		(12)
Fair Value	42,907		$ 53,493
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months	38,497	32,137
Unrealized Loses	(40)	(12)
U.S. Treasuries
Marketable Securities [Line Items]
Amortized cost	73,033	4,896
Unrealized Gains		1
Unrealized Losses	(23)
Fair Value	73,010	4,897
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months	73,010
Unrealized Loses	(23)
U.S. Government agencies
Marketable Securities [Line Items]
Amortized cost	78,389	28,366
Unrealized Gains	10	39
Unrealized Losses	(149)	(7)
Fair Value	78,250	28,398
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months	69,825	15,861
Unrealized Loses	(149)	(7)
Corporate bonds
Marketable Securities [Line Items]
Amortized cost	79,012	66,726
Unrealized Gains	55	289
Unrealized Losses	(136)	(8)
Fair Value	78,931	67,007
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months	48,629	8,367
Unrealized Loses	(136)	(8)
Cash and cash equivalents
Marketable Securities [Line Items]
Fair Value	$ 16,458	$ 6,893

Significant Accounting Policies

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Significant Accounting Policies

Note 3. Significant Accounting Policies

Basis of Presentation

The accompanying Consolidated Financial Statements and Notes to Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial reporting on Form 10-Q. Accordingly, certain information and disclosures required for complete financial statements prepared in accordance with U.S. GAAP are not included herein. The Consolidated Balance Sheet and related information as of December 31, 2023 included herein was derived from the restated audited Consolidated Financial Statements as of December 31, 2023 (as restated), but does not include all disclosures required by U.S. GAAP on an annual reporting basis. Certain amounts in the prior years’ Consolidated Financial Statements have been reclassified to conform to the current year’s presentation.

These Consolidated Financial Statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, originally filed with the SEC on February 29, 2024 (the “Original Annual Report”), and Amendment No. 1 to the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2023, filed with the SEC on December 23, 2024. Since the date of the Original Annual Report, there have been no changes or updates to the Company’s significant accounting policies, other than those described below.

In the opinion of management, the Consolidated Financial Statements and Notes to Consolidated Financial Statements contain all normal, recurring adjustments necessary for a fair statement of financial position, results of operations, comprehensive loss, and cash flows as of the dates and for the interim periods presented. The results of operations for the three months ended March 31, 2024 may not be indicative of the results for the full year ended December 31, 2024, or any other period.

The Company’s fiscal year is the twelve-month period from January 1 through December 31, and all references to “2024,” “2023,” and the like refer to the fiscal year unless otherwise noted.

Use of Estimates

The preparation of the Consolidated Financial Statements and Notes to Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the end of each fiscal period, and the reported amounts of revenues and expenses during each fiscal period. Such estimates include, but are not limited to, revenue recognition, valuation of inventory, leases, valuation and impairment of intangible and long-lived assets, recoverability of deferred tax assets, and stock-based compensation expense. The Company bases its estimates on historical experience, known trends, worldwide economic conditions, both general and specific to the life sciences industry, and other relevant factors it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates and changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

Principles of Consolidation

The Consolidated Financial Statements and Notes to Consolidated Financial Statements include the accounts of Quanterix and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation.

In accordance with Accounting Standards Codification (“ASC”) 810 – Consolidation, the Company assesses the terms of non-marketable equity investments in entities to determine if any meet the definition of a variable interest entity (“VIE”) and require consolidation into its Consolidated Financial Statements. Refer to Note 15 − Variable Interest Entities for further discussion.

Foreign Currency

The functional currency of the Company’s subsidiaries is their respective local currencies. These subsidiary financial statements are translated into U.S. dollars using the period-end exchange rates for assets and liabilities, average exchange rates during the corresponding period for revenue and expenses, and historical rates for equity. The effects of foreign currency translation adjustments are recorded in accumulated other comprehensive income (loss), a component of stockholders’ equity on the Consolidated Balance Sheets.

Foreign currency transaction gains (losses) are included in other income, net on the Consolidated Statements of Operations and were not material for the three months ended March 31, 2024 and 2023.

Restricted Cash

The following table summarizes the period ending cash and cash equivalents as presented on the Consolidated Balance Sheets and the total cash, cash equivalents, and restricted cash as presented on the Consolidated Statements of Cash Flows (in thousands):


	As of March 31,
	2024		2023
			(As Restated)
Cash and cash equivalents	$	45,281	$	329,354
Restricted cash	2,605		2,598
Cash, cash equivalents, and restricted cash	$	47,886	$	331,952

Restricted cash consists of collateral for a letter of credit issued as security for two of the Company’s leased facilities and to secure the Company’s corporate credit card program. The short-term or long-term classification is determined in accordance with the expiration of the underlying letter of credit and security.

Recently Adopted Accounting Pronouncements

In June 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). This update clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. The new standard became effective for the Company on January 1, 2024. The Company adopted this standard on a prospective basis and such adoption did not have a material impact on the Company’s Consolidated Financial Statements or related disclosures.

Recent Accounting Standards to be Adopted

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard enhances the disclosures of reportable segment information, primarily with regards to significant segment expenses, and applies to entities with a single reportable segment. The new standard is effective for the Company for annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adoption of the standard on its Consolidated Financial Statements disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new standard enhances income tax disclosure requirements by requiring specified categories and greater disaggregation within the tax rate reconciliation table, disclosure of income taxes paid by jurisdiction, and providing clarification on uncertain tax positions and related financial statement impacts. The new standard is effective for the Company for annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the impact of adoption of the standard on its Consolidated Financial Statements disclosures.

Variable Interest Entities (As Restated)	3 Months Ended
Variable Interest Entities (As Restated)	Mar. 31, 2024
Variable Interest Entities
Variable Interest Entities (As Restated)	Note 15. Variable Interest Entities (As Restated) The Company enters into relationships with, or has investments in, other entities that may be VIEs. The Company assesses the criteria in ASC 810 – Consolidation to determine if any of these entities meet the definition of a VIE and require consolidation into its financial statements. The Company’s analysis determines whether it has a controlling financial interest and also identifies the primary beneficiary of a VIE as the enterprise that has both (1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. Based on the Company’s assessments, it does not have any controlling financial interests in any VIE, and therefore did not consolidate any VIE into its Consolidated Financial Statements during the three months ended March 31, 2024 and 2023. As of March 31, 2024 and December 31, 2023, the carrying value of the Company’s investment in a VIE was $0.8 million, which was recorded in other non-current assets on the Consolidated Balance Sheets. Refer to Note 7 − Fair Value of Financial Instruments for the Company’s related valuation disclosures. Maximum exposure to losses related to the VIE is limited to its carrying value and the Company does not have any future funding commitments to the VIE.

Revenue Recognition - Deferred Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Deferred Revenue, Revenue Recognized	$ 2.7	$ 2.4

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 32,066	$ 28,456
Costs of goods sold and services:
Total costs of goods sold and services	13,518	12,463
Gross profit	18,548	15,993
Operating expenses:
Research and development	6,742	4,987
Selling, general and administrative	26,039	20,784
Other lease costs	924	800
Total operating expenses	33,705	26,571
Loss from operations	(15,157)	(10,578)
Interest income (expense), net	3,948	3,449
Other income (expense), net	226	(5)
Loss before income taxes	(10,983)	(7,134)
Income tax (expense) benefit	(180)	(140)
Net loss	$ (11,163)	$ (7,274)
Net loss per common share, basic (in dollars per share)	$ (0.29)	$ (0.19)
Net loss per common share, diluted (in dollars per share)	$ (0.29)	$ (0.19)
Weighted-average common shares outstanding, basic (in shares)	38,126,000	37,327,000
Weighted-average common shares outstanding, diluted (in shares)	38,126,000	37,327,000
Product revenue
Revenues:
Total revenues	$ 19,670	$ 19,360
Costs of goods sold and services:
Total costs of goods sold and services	8,237	7,879
Service revenue
Revenues:
Total revenues	11,967	8,506
Service revenue
Revenues:
Total revenues	11,967	8,506
Costs of goods sold and services:
Total costs of goods sold and services	5,281	4,584
Collaboration and license revenue
Revenues:
Total revenues	155	368
Grant revenue
Revenues:
Total revenues	$ 274	$ 222

Restatement of Financial Statements

3 Months Ended

Mar. 31, 2024

Accounting Changes and Error Corrections [Abstract]

Restatement of Financial Statements

Note 1. Restatement of Financial Statements

Subsequent to the issuance of Quanterix Corporation's (“Quanterix” or the “Company”) Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 8, 2024 (the “Original Report”), the Company identified an error related to the capitalization of labor and overhead costs in the Company's inventory balances (the “Misstatement”), which impacted the previously issued unaudited Consolidated Financial Statements as of March 31, 2024, for the quarterly periods ended March 31, 2024 and 2023, and the audited Consolidated Financial Statements as of December 31, 2023 (the “Restatement Periods”). In accordance with ASC 250 - Accounting Changes and Error Corrections, SEC Staff Accounting Bulletin (“SAB”) No. 99 - Materiality, and SAB No. 108 - Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, management concluded the error was material to the Company’s financial statements and required restatement of the financial statements for the Restatement Periods (the “Restatement”). In connection with the Restatement, the Company is also correcting unrelated errors identified by the Company in prior periods.

Restatement Background

In connection with the Company's efforts to remediate a material weakness in its internal control over financial reporting relating to the operating effectiveness of internal controls associated with the accounting for inventory valuation, and while performing closing procedures for the third quarter of 2024, the Company identified the Misstatement. The correction of the Misstatement impacts the previously reported amounts of inventory, cost of product revenue, net loss per common share, and all related financial statement subtotals and totals. In addition, the correction of unrelated errors identified by the Company in prior periods includes, but is not limited to, adjustments to property and equipment, accrued compensation and benefits, and operating expenses (together with the Misstatement, the “Combined Misstatements”).

Impact of Restatement

The following tables present the impact of the Restatement to the specific line items presented in the previously reported unaudited Consolidated Financial Statements in all Restatement Periods. The amounts labeled "As Previously Reported" were derived from the Original Report. The amounts labeled “Adjustments” represent the impact of correcting the Combined Misstatements identified by the Company. The effects of the Restatement have been corrected in all impacted tables and footnotes throughout the Consolidated Financial Statements herein.

QUANTERIX CORPORATION

RESTATED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except per share data)


	As of March 31, 2024
	As Previously Reported		Adjustments		As Restated
ASSETS
Current assets:
Cash and cash equivalents	$	45,281	$	—	$	45,281
Marketable securities	256,640		—		256,640
Accounts receivable, net of allowance for expected credit losses	29,276		—		29,276
Inventory	26,015		2,619		28,634
Prepaid expenses and other current assets	9,551		(30)		9,521
Total current assets	366,763		2,589		369,352
Restricted cash	2,605		—		2,605
Property and equipment, net	17,492		—		17,492
Intangible assets, net	5,339		—		5,339
Operating lease right-of-use assets	17,748		—		17,748
Other non-current assets	1,802		(133)		1,669
Total assets	$	411,749	$	2,456	$	414,205
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	3,914	$	65	$	3,979
Accrued compensation and benefits	6,706		490		7,196
Accrued expenses and other current liabilities	7,021		(39)		6,982
Deferred revenue	10,234		—		10,234
Operating lease liabilities	4,366		—		4,366
Total current liabilities	32,241		516		32,757
Deferred revenue, net of current portion	933		—		933
Operating lease liabilities, net of current portion	36,084		—		36,084
Other non-current liabilities	1,053		—		1,053
Total liabilities	70,311		516		70,827
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.001 par value per share:
Authorized: 120,000 shares; issued and outstanding: 38,288 shares at March 31, 2024	38		—		38
Additional paid-in capital	789,006		—		789,006
Accumulated other comprehensive loss	(3,038)		85		(2,953)
Accumulated deficit	(444,568)		1,855		(442,713)
Total stockholders’ equity	341,438		1,940		343,378
Total liabilities and stockholders’ equity	$	411,749	$	2,456	$	414,205


	As of December 31, 2023
	As Previously Reported		Adjustments		As Restated
ASSETS
Current assets:
Cash and cash equivalents	$	174,422	$	—	$	174,422
Marketable securities	146,902		—		146,902
Accounts receivable, net of allowance for expected credit losses	25,414		—		25,414
Inventory	22,365		3,758		26,123
Prepaid expenses and other current assets	9,291		(57)		9,234
Total current assets	378,394		3,701		382,095
Restricted cash	2,604		—		2,604
Property and equipment, net	17,926		—		17,926
Intangible assets, net	6,034		—		6,034
Operating lease right-of-use assets	18,251		—		18,251
Other non-current assets	1,802		(145)		1,657
Total assets	$	425,011	$	3,556	$	428,567
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	5,048	$	—	$	5,048
Accrued compensation and benefits	13,659		511		14,170
Accrued expenses and other current liabilities	6,041		14		6,055
Deferred revenue	9,468		—		9,468
Operating lease liabilities	4,241		—		4,241
Total current liabilities	38,457		525		38,982
Deferred revenue, net of current portion	1,227		—		1,227
Operating lease liabilities, net of current portion	37,223		—		37,223
Other non-current liabilities	1,177		—		1,177
Total liabilities	78,084		525		78,609
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.001 par value per share:
Authorized: 120,000 shares; issued and outstanding: 38,014 shares at December 31, 2023	38		—		38
Additional paid-in capital	783,142		—		783,142
Accumulated other comprehensive loss	(1,757)		85		(1,672)
Accumulated deficit	(434,496)		2,946		(431,550)
Total stockholders’ equity	346,927		3,031		349,958
Total liabilities and stockholders’ equity	$	425,011	$	3,556	$	428,567

QUANTERIX CORPORATION

RESTATED CONSOLIDATED STATEMENTS OF OPERATIONS

(amounts in thousands, except per share data)


	Three Months Ended March 31, 2024						Three Months Ended March 31, 2023
	As Previously Reported		Adjustments		As Restated		As Previously Reported		Adjustments		As Restated
Revenues:
Product revenue	$	19,670	$	—	$	19,670	$	19,287	$	73	$	19,360
Service revenue	11,967		—		11,967		8,579		(73)		8,506
Collaboration and license revenue	155		—		155		368		—		368
Grant revenue	274		—		274		222		—		222
Total revenues	32,066		—		32,066		28,456		—		28,456
Costs of goods sold and services:
Cost of product revenue	7,145		1,092		8,237		7,033		846		7,879
Cost of service and other revenue	5,295		(14)		5,281		4,497		87		4,584
Total costs of goods sold and services	12,440		1,078		13,518		11,530		933		12,463
Gross profit	19,626		(1,078)		18,548		16,926		(933)		15,993
Operating expenses:
Research and development	6,675		67		6,742		4,720		267		4,987
Selling, general, and administrative	25,993		46		26,039		20,850		(66)		20,784
Other lease costs	924		—		924		776		24		800
Total operating expenses	33,592		113		33,705		26,346		225		26,571
Loss from operations	(13,966)		(1,191)		(15,157)		(9,420)		(1,158)		(10,578)
Interest income	3,948		—		3,948		3,449		—		3,449
Other income (expense), net	206		20		226		8		(13)		(5)
Loss before income taxes	(9,812)		(1,171)		(10,983)		(5,963)		(1,171)		(7,134)
Income tax expense	(260)		80		(180)		(140)		—		(140)
Net loss	$	(10,072)	$	(1,091)	$	(11,163)	$	(6,103)	$	(1,171)	$	(7,274)

Net loss per common share, basic and diluted	$	(0.26)	$	(0.03)	$	(0.29)	$	(0.16)	$	(0.03)	$	(0.19)

Weighted-average common shares outstanding, basic and diluted	38,126		—		38,126		37,327		—		37,327

QUANTERIX CORPORATION

RESTATED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(amounts in thousands)


	Three Months Ended March 31, 2024						Three Months Ended March 31, 2023
	As Previously Reported		Adjustments		As Restated		As Previously Reported		Adjustments		As Restated
Net loss	$	(10,072)	$	(1,091)	$	(11,163)	$	(6,103)	$	(1,171)	$	(7,274)
Other comprehensive income (loss), net of tax:
Unrealized losses on marketable securities	(607)		—		(607)		—		—		—
Foreign currency translation adjustment	(674)		—		(674)		42		—		42
Total other comprehensive income (loss)	(1,281)		—		(1,281)		42		—		42
Comprehensive loss	$	(11,353)	$	(1,091)	$	(12,444)	$	(6,061)	$	(1,171)	$	(7,232)

QUANTERIX CORPORATION

RESTATED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(amounts in thousands)


	Three Months Ended March 31, 2024
	Common Stock
As Previously Reported	Shares	Amount		Additional paid-in capital		Accumulated other comprehensive income (loss)		Accumulated deficit		Total stockholders' equity
Balance at December 31, 2023	38,014	$	38	$	783,142	$	(1,757)	$	(434,496)	$	346,927
Issuance of common stock under stock plans, including tax effects	274	—		599		—		—		599
Stock-based compensation expense	—	—		5,265		—		—		5,265
Unrealized loss on marketable securities, net of tax	—	—		—		(607)		—		(607)
Foreign currency translation adjustment	—	—		—		(674)		—		(674)
Net loss	—	—		—		—		(10,072)		(10,072)
Balance at March 31, 2024	38,288	$	38	$	789,006	$	(3,038)	$	(444,568)	$	341,438

Adjustments
Balance at December 31, 2023	—	$	—	$	—	$	85	$	2,946	$	3,031
Issuance of common stock under stock plans, including tax effects	—	—		—		—		—		—
Stock-based compensation expense	—	—		—		—		—		—
Unrealized loss on marketable securities, net of tax	—	—		—		—		—		—
Foreign currency translation adjustment	—	—		—		—		—		—
Net loss	—	—		—		—		(1,091)		(1,091)
Balance at March 31, 2024	—	$	—	$	—	$	85	$	1,855	$	1,940
As Restated
Balance at December 31, 2023	38,014	$	38	$	783,142	$	(1,672)	$	(431,550)	$	349,958
Issuance of common stock under stock plans, including tax effects	274	—		599		—		—		599
Stock-based compensation expense	—	—		5,265		—		—		5,265
Unrealized loss on marketable securities, net of tax	—	—		—		(607)		—		(607)
Foreign currency translation adjustment	—	—		—		(674)		—		(674)
Net loss	—	—		—		—		(11,163)		(11,163)
Balance at March 31, 2024	38,288	$	38	$	789,006	$	(2,953)	$	(442,713)	$	343,378


	Three Months Ended March 31, 2023
	Common Stock
As Previously Reported	Shares	Amount		Additional paid-in capital		Accumulated other comprehensive income (loss)		Accumulated deficit		Total stockholders' equity
Balance at December 31, 2022	37,280	$	37	$	763,688	$	(2,623)	$	(402,162)	$	358,940
Issuance of common stock under stock plans, including tax effects	144	—		551		—		—		551
Stock-based compensation expense	—	—		3,902		—		—		3,902
Foreign currency translation adjustment	—	—		—		42		—		42
Net loss	—	—		—		—		(6,103)		(6,103)
Balance at March 31, 2023	37,424	$	37	$	768,141	$	(2,581)	$	(408,265)	$	357,332
Adjustments
Balance at December 31, 2022	—	$	—	$	(59)	$	85	$	(1,034)	$	(1,008)
Issuance of common stock under stock plans, including tax effects	—	—		—		—		—		—
Stock-based compensation expense	—	—		41		—		—		41
Foreign currency translation adjustment	—	—		—		—		—		—
Net loss	—	—		—		—		(1,171)		(1,171)
Balance at March 31, 2023	—	$	—	$	(18)	$	85	$	(2,205)	$	(2,138)
As Restated
Balance at December 31, 2022	37,280	$	37	$	763,629	$	(2,538)	$	(403,196)	$	357,932
Issuance of common stock under stock plans, including tax effects	144	—		551		—		—		551
Stock-based compensation expense	—	—		3,943		—		—		3,943
Foreign currency translation adjustment	—	—		—		42		—		42
Net loss	—	—		—		—		(7,274)		(7,274)
Balance at March 31, 2023	37,424	$	37	$	768,123	$	(2,496)	$	(410,470)	$	355,194

QUANTERIX CORPORATION

RESTATED CONSOLIDATED STATEMENTS OF CASH FLOWS

(amounts in thousands)


	Three Months Ended, March 31, 2024
	As Previously Reported		Adjustments		As Restated
Cash flows from operating activities:
Net loss	$	(10,072)	$	(1,091)	$	(11,163)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,523		—		1,523
Credit losses on accounts receivable	176		—		176
Accretion of marketable securities	(1,657)		—		(1,657)
Operating lease right-of-use asset amortization	478		—		478
Stock-based compensation expense	5,265		—		5,265
Other operating activity	55		—		55
Changes in assets and liabilities:
Accounts receivable	(4,233)		—		(4,233)
Inventory	(3,670)		1,139		(2,531)
Prepaid expenses and other current assets	(254)		(27)		(281)
Other non-current assets	(21)		(12)		(33)
Accounts payable	(1,122)		65		(1,057)
Accrued compensation and benefits, accrued expenses, and other current liabilities	(6,126)		(74)		(6,200)
Deferred revenue	472		—		472
Operating lease liabilities	(988)		—		(988)
Other non-current liabilities	10		—		10
Net cash used in operating activities	(20,164)		—		(20,164)
Cash flows from investing activities:
Purchases of marketable securities	(137,889)		—		(137,889)
Proceeds from maturities of marketable securities	29,200		—		29,200
Purchases of property and equipment	(506)		—		(506)
Net cash used in investing activities	(109,195)		—		(109,195)
Cash flows from financing activities:
Proceeds from common stock issued under stock plans	2,037		—		2,037
Payments for employee taxes withheld on stock-based compensation awards	(1,438)		—		(1,438)
Net cash provided by financing activities	599		—		599
Net decrease in cash, cash equivalents, and restricted cash	(128,760)		—		(128,760)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(380)		—		(380)
Cash, cash equivalents, and restricted cash at beginning of period	177,026		—		177,026
Cash, cash equivalents, and restricted cash at end of period	$	47,886	$	—	$	47,886

Supplemental disclosure of cash flow information:
Cash paid for taxes	$	175	$	—	$	175
Purchases of property and equipment in accounts payable and accruals	$	222	$	—	$	222


	Three Months Ended, March 31, 2023
	As Previously Reported		Adjustments		As Restated
Cash flows from operating activities:
Net loss	$	(6,103)	$	(1,171)	$	(7,274)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,439		15		1,454
Credit losses on accounts receivable	178		—		178
Operating lease right-of-use asset amortization	334		—		334
Stock-based compensation expense	3,902		41		3,943
Other operating activity	270		—		270
Changes in assets and liabilities:
Accounts receivable	(3,741)		—		(3,741)
Inventory	(89)		619		530
Prepaid expenses and other current assets	(422)		—		(422)
Other non-current assets	(33)		—		(33)
Accounts payable	(1,271)		—		(1,271)
Accrued compensation and benefits, accrued expenses, and other current liabilities	(5,983)		174		(5,809)
Deferred revenue	2,041		—		2,041
Operating lease liabilities	179		—		179
Other non-current liabilities	(203)		—		(203)
Net cash used in operating activities	(9,502)		(322)		(9,824)
Cash flows from investing activities:
Purchases of property and equipment	(136)		—		(136)
Net cash used in investing activities	(136)		—		(136)
Cash flows from financing activities:
Proceeds from common stock issued under stock plans	564		—		564
Payments for employee taxes withheld on stock-based compensation awards	(13)		—		(13)
Net cash provided by financing activities	551		—		551
Net decrease in cash, cash equivalents, and restricted cash	(9,087)		(322)		(9,409)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	24		—		24
Cash, cash equivalents, and restricted cash at beginning of period	341,337		—		341,337
Cash, cash equivalents, and restricted cash at end of period	$	332,274	$	(322)	$	331,952

Supplemental disclosure of cash flow information:
Cash paid for taxes	$	246	$	—	$	246
Purchases of property and equipment in accounts payable and accruals	$	147	$	—	$	147

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2024	May 02, 2024
Cover [Abstract]
Document Type	10-Q/A
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-38319
Entity Registrant Name	Quanterix Corp
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-8957988
Entity Address, Address Line One	900 Middlesex Turnpike
Entity Address, City or Town	Billerica
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01821
City Area Code	617
Local Phone Number	301-9400
Title of 12(g) Security	Common Stock, $0.001 par value per share
Trading Symbol	QTRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		38,270,088
Entity Central Index Key	0001503274
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	true
Amendment Description	EXPLANATORY NOTEOverviewQuanterix Corporation (“it”, “Quanterix” or the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (the “Amended Report”) to amend and restate certain items in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 8, 2024 (the “Original Report”), in order to reflect the effects of the restatement of the financial statements included therein (the “Restatement”). This Amended Report includes the Company’s restated unaudited Consolidated Financial Statements as of March 31, 2024, for the quarterly periods ended March 31, 2024 and 2023, and the Company's restated audited Consolidated Financial Statements as of December 31, 2023 to correct an error related to its inventory valuation and to correct certain other unrelated errors. On December 23, 2024, the Company also filed Amendment No. 1 to its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023, originally filed with the SEC on February 29, 2024 (the “Amended Annual Report”), to amend and restate certain items in such report and to include the Company’s restated audited Consolidated Financial Statements as of December 31, 2023 and 2022 and for each of the three years in the period ended December, 31 2023 and its unaudited Consolidated Financial Statements for all of the quarterly and year-to-date (as applicable) periods of 2023 and 2022. In addition, the Company is separately filing an amendment to its Quarterly Report on Form 10-Q/A for the quarterly period ended June 30, 2024, originally filed with the SEC on August 8, 2024 (collectively with this Amended Report and the Amended Annual Report, the “Amended Filings”), which includes restated unaudited Consolidated Financial Statements for the quarterly and year-to-date periods of 2024 and 2023 covered by such report.Restatement BackgroundAs previously disclosed by the Company in its Current Report on Form 8-K filed with the SEC on November 12, 2024, in connection with its efforts to remediate a material weakness in its internal control over financial reporting relating to the operating effectiveness of internal controls associated with the accounting for inventory valuation, and while performing closing procedures for the third quarter of 2024, management identified an error related to the capitalization of labor and overhead costs in the Company's inventory balances in prior periods (the “Misstatement”). The error was not caused by any override of controls, misconduct, or fraud. The correction of the Misstatement impacts the previously reported amounts of inventory, cost of product revenue, net loss per common share, and all related financial statement subtotals and totals. In addition to correcting the Misstatement, the Amended Filings also reflect adjustments to correct unrelated errors to other financial statement line items identified by the Company in prior periods which include, but are not limited to, adjustments to property and equipment, accrued compensation and benefits, and operating expenses.Refer to Note 1 - Restatement of Financial Statements in the Notes to Consolidated Financial Statements for more information related to the Restatement, including the impact on the Company’s Consolidated Financial Statements.Internal Control ConsiderationsIn connection with preparing this Amended Report, management has updated its evaluation of the effectiveness of its internal control over financial reporting as of March 31, 2024, as further described in Part I, Item 4. “Controls and Procedures” of this Amended Report. Consistent with the conclusion in Part II, Item 9A. “Controls and Procedures” of the Amended Annual Report, management continued to conclude that its internal control over financial reporting and disclosure controls and procedures were not effective as of March 31, 2024 due to the previously identified material weaknesses in its internal control over financial reporting, including that the material weakness in the controls relating to the operating effectiveness over accounting for inventory valuation should reflect the additional internal control design deficiency associated with the Misstatement.Items Amended in this Amended ReportThis Amended Report amends and restates the sections of the Original Report listed below, with modifications as necessary to reflect the Restatement. No attempt has been made in this Amended Report to update other disclosures in the Original Report, except as required to reflect the effects of the Restatement in the following amended items:•Note Regarding Forward-Looking Statements•Part I, Item 1. Financial Statements (Unaudited)•Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations•Part I, Item 4. Controls and Procedures•Part II, Item 6. ExhibitsExcept as described above, this Amended Report does not amend, update, or change any other disclosures in the Original Report. Among other things, except as related to the Restatement, forward looking statements made in the Original Report have not been revised to reflect events that occurred or facts that became known to the Company after the filing of the Original Report, and such forward looking statements should be read in their historical context. As such, this Amended Report speaks only as of the date the Original Report was filed, and the Company has not undertaken herein to amend, supplement, or update any information contained in the Original Report to give effect to any subsequent events. Accordingly, this Amended Report should be read in conjunction with the Original Report, including any other filings with the SEC.In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s Chief Executive Officer (as principal executive officer) and Chief Financial Officer (as principal financial officer) are filed herewith as Exhibits 31.1, 31.2 and 32.1 to this Amendment pursuant to Rule 13a-14(a) of the Exchange Act and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350).

Accrued Expenses and Other Current Liabilities

3 Months Ended

Mar. 31, 2024

Accrued Expenses and Other Current Liabilities

Accrued Expenses and Other Current Liabilities

Note 9. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31, 2024		December 31, 2023
	(As Restated)		(As Restated)
Accrued professional services	$	1,947	$	1,596
Accrued royalties	1,631		1,689
Accrued tax liabilities	1,446		822
Other accrued expenses	1,958		1,948
Total accrued expenses and other current liabilities	$	6,982	$	6,055

Leases - Balance Sheet information (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Lessee Disclosure [Abstract]
Operating lease ROU assets	$ 17,748	$ 18,251
Short-term operating lease liabilities	4,366	4,241
Non-current operating lease liabilities	36,084	$ 37,223
Total operating lease liabilities	$ 40,450

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional paid-in capital	Accumulated other comprehensive income (loss)	Accumulated deficit
Beginning Balance at Dec. 31, 2022	$ 357,932	$ 37	$ 763,629	$ (2,538)	$ (403,196)
Beginning balance (in shares) at Dec. 31, 2022		37,280
Increase (Decrease) in Stockholders' Equity
Issuance of common stock under stock plans, including tax effects	551		551
Issuance of common stock under stock plans, including tax effects (in shares)		144
Stock-based compensation expense	3,943		3,943
Unrealized loss on marketable securities, net of tax	0
Foreign currency translation adjustment	42			42
Net loss	(7,274)				(7,274)
Ending Balance at Mar. 31, 2023	355,194	$ 37	768,123	(2,496)	(410,470)
Ending Balance (in shares) at Mar. 31, 2023		37,424
Beginning Balance at Dec. 31, 2023	349,958	$ 38	783,142	(1,672)	(431,550)
Beginning balance (in shares) at Dec. 31, 2023		38,014
Increase (Decrease) in Stockholders' Equity
Issuance of common stock under stock plans, including tax effects	599		599
Issuance of common stock under stock plans, including tax effects (in shares)		274
Stock-based compensation expense	5,265		5,265
Unrealized loss on marketable securities, net of tax	(607)			(607)
Foreign currency translation adjustment	(674)			(674)
Net loss	(11,163)				(11,163)
Ending Balance at Mar. 31, 2024	$ 343,378	$ 38	$ 789,006	$ (2,953)	$ (442,713)
Ending Balance (in shares) at Mar. 31, 2024		38,288

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

Related Party Transactions (Details) - USD ($)	3 Months Ended
Related Party Transactions (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Related party transactions
Cost of revenue	$ 13,518,000	$ 12,463,000
Accounts receivable	29,276,000		$ 25,414,000
Accounts payable	3,979,000		$ 5,048,000
Harvard University
Related party transactions
Related party revenue	300,000	300,000
Cost of revenue	0	$ 0
UltraDx Limited Company
Related party transactions
Related party revenue	1,100,000
Cost of revenue	0
Accounts receivable	1,200,000
Accounts payable	$ 0

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

+ Details

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 14. Related Party Transactions In June 2007, the Company entered into the Tufts License Agreement for certain intellectual property owned by Tufts (refer to Note 13 − Commitments and Contingencies). A member of the Company’s Board of Directors was previously affiliated with Tufts and continues to receive compensation from Tufts on a formulaic basis based on royalties and license payments the Company makes to Tufts. At March 31, 2024 and December 31, 2023, open payable balances to Tufts were not material. In August 2022, the Company entered into the Harvard License Agreement for certain intellectual property owned by Harvard (refer to Note 13 − Commitments and Contingencies). Harvard is required to pay a portion of the payments received from the Company under the Harvard License Agreement to a member of the Company’s Board of Directors. A member of the Company’s Board of Directors is also affiliated with Harvard and Mass General Brigham. Revenue recorded from sales of products and services to Harvard and its affiliates and to Mass General Brigham and its affiliates was $0.3 million for both the three months ended March 31, 2024 and 2023. Cost of product revenue and operating expenses with Harvard and Mass General Brigham were not material for the three months ended March 31, 2024 and 2023. At March 31, 2024 and December 31, 2023, open payables to and receivable balances from Harvard and Mass General Brigham were not material. In May 2022, the Company and UltraDx Limited (“UltraDx”), a company formed by ARCH Venture Partners (“ARCH”), entered into an agreement (the “UltraDx Agreement”). Under the UltraDx Agreement, the Company agreed to supply UltraDx with HD-X instruments (both fully assembled and disassembled), assays and assay components, and granted a co-exclusive license to manufacture, seek Chinese regulatory approval of (including performance of any necessary research and development activities), and commercialize, HD-X instruments assembled in China and related assays in the Chinese IVD market. At contract inception, the Company determined that UltraDx was a related party because a member of the Company’s Board of Directors was affiliated with ARCH and UltraDx. As of June 7, 2023, this individual was no longer a member of the Company’s Board of Directors. Revenue recorded from sales of products and services to UltraDx totaled $1.1 million for the three months ended March 31, 2024. Cost of product revenue and services was not material for the three months ended March 31, 2024. At March 31, 2024 there was $1.2 million in open receivable balances and no open payable balances to UltraDx. Revenue and cost of product revenue and services for three months ended March 31, 2023 were not material. At December 31, 2023, there were no open payable balances to UltraDx and open receivable balances from UltraDx were not material.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Schedule of fair value measurements

Recurring Fair Value Measurements

The following tables present the Company’s fair value hierarchy for its financial assets that are measured at fair value on a recurring basis (in thousands):


As of March 31, 2024	Total		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Financial assets:
Cash equivalents: (1)
Money market funds	$	19,792	$	19,792	$	—	$	—
U.S. Treasuries	16,458		—		16,458		—
Total cash equivalents	36,250		19,792		16,458		—
Marketable securities:
Commercial paper	42,907		—		42,907		—
U.S. Treasuries	56,552		—		56,552		—
U.S. Government agency bonds	78,250		—		78,250		—
Corporate bonds	78,931		—		78,931		—
Total marketable securities	256,640		—		256,640		—
Total financial assets	$	292,890	$	19,792	$	273,098	$	—


As of December 31, 2023	Total		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Financial assets:
Cash equivalents: (1)
Money market funds	$	155,367	$	155,367	$	—	$	—
Commercial paper	1,996		—		1,996		—
U.S. Treasuries	4,897		—		4,897		—
Total cash equivalents	162,260		155,367		6,893		—
Marketable securities:
Commercial paper	51,498		—		51,498		—
U.S. Government agency bonds	28,398		—		28,398		—
Corporate bonds	67,006		—		67,006		—
Total marketable securities	146,902		—		146,902		—
Total financial assets	$	309,162	$	155,367	$	153,795	$	—

(1)Included in cash and cash equivalents on the Consolidated Balance Sheets.

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (11,163)	$ (7,274)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,523	1,454
Credit losses (gains) on accounts receivable	176	178
Amortization of (discount) premium on marketable securities	(1,657)	0
Operating lease right-of-use asset amortization	478	334
Stock-based compensation expense	5,265	3,943
Other operating activity	55	270
Changes in assets and liabilities:
Accounts receivable	(4,233)	(3,741)
Inventory	(2,531)	530
Prepaid expenses and other current assets	(281)	(422)
Other non-current assets	(33)	(33)
Accounts payable	(1,057)	(1,271)
Accrued compensation and benefits, accrued expenses, and other current liabilities	(6,200)	(5,809)
Deferred revenue	472	2,041
Operating lease liabilities	(988)	179
Other non-current liabilities	10	(203)
Net cash used in operating activities	(20,164)	(9,824)
Cash flows from investing activities:
Purchases of marketable securities	(137,889)	0
Proceeds from maturities of marketable debt securities	29,200	0
Purchases of property and equipment	(506)	(136)
Net cash used in investing activities	(109,195)	(136)
Cash flows from financing activities:
Proceeds from common stock issued under stock plans	2,037	564
Payments for employee taxes withheld on stock-based compensation awards	(1,438)	(13)
Net cash provided by financing activities	599	551
Net increase (decrease) in cash, cash equivalents, and restricted cash	(128,760)	(9,409)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(380)	24
Cash, cash equivalents, and restricted cash at beginning of period	177,026	341,337
Cash, cash equivalents, and restricted cash at end of period	47,886	331,952
Supplemental disclosure of cash flow information:
Cash paid for taxes	175	246
Purchases of property and equipment in accounts payable and accruals	$ 222	$ 147

Commitments and contingencies

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

Note 13. Commitments and Contingencies

Purchase Commitments

STRATEC

During 2022, the Company and STRATEC Consumables GmbH (“STRATEC”) entered into an amendment to the supply agreement with STRATEC (as amended, the “STRATEC Supply Agreement”), related to the supply of discs used in Simoa bead-based instruments. As part of the STRATEC Supply Agreement, the Company agreed to purchase a total of 515 thousand discs to be shipped at various points starting in 2022 and continuing through 2024 at an agreed purchase price per disc.

The total purchase commitment under the STRATEC Supply Agreement is $3.7 million, of which $2.1 million has been paid, and $1.6 million is due within one year from March 31, 2024.

During the three months ended March 31, 2024 and 2023, STRATEC shipped 35 thousand and 75 thousand discs, respectively, to the Company. The Company recorded cost of product revenue related to these shipments of $0.3 million and $0.5 million for the three months ended March 31, 2024 and 2023, respectively. During 2024, STRATEC is required to ship 222 thousand discs to the Company. During the three months ended March 31, 2024, 35 thousand discs were shipped.

Other Purchase Commitments

The Company’s other non-cancellable purchase commitments primarily consist of purchases of raw materials for manufacturing operations under annual and multi-year agreements, some of which have minimum quantity requirements. As of March 31, 2024, the Company’s total purchase commitments under these agreements were $3.8 million, most of which the Company expects to incur in the year ending December 31, 2024.

License Agreements

Harvard University

In August 2022, the Company and Harvard University (“Harvard”) entered into an exclusive license agreement (the “Harvard License Agreement”) for certain intellectual property owned by Harvard. Pursuant to the Harvard License Agreement, the Company paid an upfront fee of $0.6 million, which was recorded in research and development expenses on the Consolidated Statements of Operations. Under this license, the Company is required to pay Harvard low single-digit royalties on net sales of products and services using the licensed technology, as well as a portion of its applicable sublicense revenues. The Company incurred no royalty expense under the Harvard License Agreement for the three months ended March 31, 2024 and 2023.

Refer to Note 14 − Related Party Transactions for a discussion of a related party relationship with Harvard.

Tufts University

In June 2007, the Company and Tufts University (“Tufts”) entered into a license agreement (the “Tufts License Agreement”) for certain intellectual property owned by Tufts. The Tufts License Agreement, which was subsequently amended, is exclusive and sub-licensable, and will continue in effect on a country-by-country basis as long as there is a valid claim of a licensed patent in a country. The Company is required to pay license and maintenance fees that are creditable against royalties, in addition to low single-digit royalties on direct sales and services, and a royalty on sublicense income. The Company incurred royalty expenses related to the Tufts License Agreement of $0.5 million and $0.4 million during the three months ended March 31, 2024 and 2023, respectively, which was recorded in cost of product revenue on the Consolidated Statements of Operations.

Refer to Note 14 − Related Party Transactions for a discussion of a related party relationship with Tufts.

Legal Contingencies

The Company is subject to claims in the ordinary course of business; however, the Company is not currently a party to any pending or threatened litigation, the outcome of which would be expected to have a material adverse effect on its financial condition or results of operations. The Company records contingent liabilities when losses are probable and estimable. If an estimate of a probable loss is a range and no amount within the range is more likely than any other amount in the range, the Company records the minimum amount of the range.

Leases

The undiscounted future lease payments for non-cancelable operating leases were as follows (in thousands):


Maturity of lease liabilities	As of March 31, 2024
2024 (remainder)	$	5,340
2025	7,254
2026	7,408
2027	7,641
2028	7,880
2029	8,126
Thereafter	7,612
Total lease payments	51,261
Less: imputed interest	10,811
Total operating lease liabilities	$	40,450

The Company’s lease agreement for office and laboratory facilities in Bedford, Massachusetts included a tenant improvement allowance with the landlord that offset a portion of the Company’s construction costs. During the first quarter of 2023, the Company received the final tenant improvement allowance reimbursement of $0.9 million.

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Note 7. Fair Value of Financial Instruments

Recurring Fair Value Measurements

The following tables present the Company’s fair value hierarchy for its financial assets that are measured at fair value on a recurring basis (in thousands):


As of March 31, 2024	Total		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Financial assets:
Cash equivalents: (1)
Money market funds	$	19,792	$	19,792	$	—	$	—
U.S. Treasuries	16,458		—		16,458		—
Total cash equivalents	36,250		19,792		16,458		—
Marketable securities:
Commercial paper	42,907		—		42,907		—
U.S. Treasuries	56,552		—		56,552		—
U.S. Government agency bonds	78,250		—		78,250		—
Corporate bonds	78,931		—		78,931		—
Total marketable securities	256,640		—		256,640		—
Total financial assets	$	292,890	$	19,792	$	273,098	$	—


As of December 31, 2023	Total		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Financial assets:
Cash equivalents: (1)
Money market funds	$	155,367	$	155,367	$	—	$	—
Commercial paper	1,996		—		1,996		—
U.S. Treasuries	4,897		—		4,897		—
Total cash equivalents	162,260		155,367		6,893		—
Marketable securities:
Commercial paper	51,498		—		51,498		—
U.S. Government agency bonds	28,398		—		28,398		—
Corporate bonds	67,006		—		67,006		—
Total marketable securities	146,902		—		146,902		—
Total financial assets	$	309,162	$	155,367	$	153,795	$	—

(1)Included in cash and cash equivalents on the Consolidated Balance Sheets.

Cash equivalents and marketable securities classified as Level 2 financial assets are initially valued at their purchase price and subsequently valued at the end of each reporting period utilizing third party pricing services or other observable data. The pricing services utilize industry standard valuation methods, including both income and market-based approaches, and observable market inputs to determine the fair value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates, and other industry and economic events.

Nonrecurring Fair Value Measurements

The Company has a non-marketable equity investment in an entity that is evaluated under the VIE guidance (refer to Note 15 - Variable Interest Entities for further discussion). Pursuant to ASC 321 – Investments – Equity Securities, the Company uses the measurement alternative for equity investments without readily determinable fair values and recognizes its non-marketable equity investment at cost, less any impairment, and adjusted for any observable price changes in orderly transactions. The Company’s investment is classified as a Level 3 financial asset. Changes in the inputs and assumptions used to determine the fair value would result in a higher or lower fair value measurement.

The Company’s non-marketable equity investment contains certain restrictions related to the sale or transfer of the securities. The restrictions are in place indefinitely and cannot lapse. No adjustment to the fair value was required as a result of adopting ASU 2022-03 on January 1, 2024.

During the three months ended March 31, 2024 and 2023, the Company did not record any fair value adjustments to its non-marketable equity investment and to date, the cumulative fair value adjustments have not been material. As of March 31, 2024 and December 31, 2023, the carrying value of the non-marketable equity investment was $0.8 million, and is recorded in other non-current assets on the Consolidated Balance Sheets.

Other Fair Value Disclosures

During the three months ended March 31, 2024 and 2023, the Company did not transfer financial assets between levels of the fair value hierarchy. Additionally, there have been no changes to the valuation techniques for Level 2 or Level 3 financial assets.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventory (Tables)

3 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

Summary of inventory

Inventory, net of inventory reserves, consisted of the following (in thousands):


	March 31, 2024		December 31, 2023
	(As Restated)		(As Restated)
Raw materials	$	6,082	$	5,114
Work in process	8,391		5,439
Finished goods	14,161		15,570
Total inventory	$	28,634	$	26,123

Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Contract with Customer, Asset, after Allowance for Credit Loss	$ 0	$ 0

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	38,288,000	38,014,000
Common stock, shares outstanding (in shares)	38,288,000	38,014,000

Variable Interest Entities (As Restated) (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Other non-current assets	$ 1,669	$ 1,657
Variable interest entities
Other non-current assets	$ 800	$ 800

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 45,281	$ 174,422	$ 329,354
Marketable securities	256,640	146,902
Accounts receivable, net of allowance for expected credit losses	29,276	25,414
Inventory	28,634	26,123
Prepaid expenses and other current assets	9,521	9,234
Total current assets	369,352	382,095
Restricted cash	2,605	2,604
Property and equipment, net	17,492	17,926
Intangible assets, net	5,339	6,034
Operating lease right-of-use assets	17,748	18,251
Other non-current assets	1,669	1,657
Total assets	414,205	428,567
Current liabilities:
Accounts payable	3,979	5,048
Accrued compensation and benefits	7,196	14,170
Accrued expenses and other current liabilities	6,982	6,055
Deferred revenue	10,234	9,468
Short-term operating lease liabilities	4,366	4,241
Total current liabilities	32,757	38,982
Deferred revenue, net of current portion	933	1,227
Non-current operating lease liabilities	36,084	37,223
Other non-current liabilities	1,053	1,177
Total liabilities	70,827	78,609
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, $0.001 par value, per share: Authorized: XXX,XXX; issued and outstanding: 38,014 and 37,280 shares at December 31, 2023 and 2022, respectively	38	38
Additional paid-in capital	789,006	783,142
Accumulated other comprehensive loss	(2,953)	(1,672)
Accumulated deficit	(442,713)	(431,550)
Total stockholders' equity	343,378	349,958	$ 355,194	$ 357,932
Total liabilities and stockholders' equity	$ 414,205	$ 428,567

Stock-Based Compensation

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

Stock Options

Stock option activity for the three months ended March 31, 2024 is presented below (in thousands, except per share and contractual life amounts):


	Number of options	Weighted-average exercise price per share		Weighted-average remaining contractual life (in years)	Aggregate intrinsic value
Outstanding at December 31, 2023	2,774	$	19.62	7.9	$	26,941
Granted	1,179	22.74
Exercised	(104)	12.34
Forfeited/expired	(181)	20.24
Outstanding at March 31, 2024	3,668	$	20.80	8.3	$	17,741
Exercisable at March 31, 2024	1,297	$	22.24	6.6	$	7,615
Vested and expected to vest at March 31, 2024	3,668	$	20.80	8.3	$	17,741

Restricted Stock Units

Restricted stock unit (“RSU”) activity for the three months ended March 31, 2024 is presented below (in thousands, except per share amounts):


	Number of shares	Weighted-average grant date fair value per share
Unvested at December 31, 2023	1,328	$	17.87
Granted	446	24.40
Vested	(197)	17.57
Forfeited	(96)	20.52
Unvested at March 31, 2024	1,481	$	19.71

Employee Stock Purchase Plan (“ESPP”)

In December 2017, the Company adopted the 2017 Employee Stock Purchase Plan (the “2017 ESPP”). The 2017 ESPP provides for six-month offering periods commencing and ending as follows: March 1 through August 31, and September 1 through February 28. During the three months ended March 31, 2024, employees purchased 36 thousand shares of the Company’s common stock pursuant to the 2017 ESPP.

Stock-Based Compensation Expense

Stock-based compensation expense was recorded in the following categories on the Consolidated Statements of Operations (in thousands):


	Three Months Ended March 31,
	2024		2023
			(As Restated)
Cost of product revenue	$	281	$	197
Cost of service and other revenue	308		350
Research and development	543		379
Selling, general and administrative	4,133		3,017
Total stock-based compensation expense	$	5,265	$	3,943

As of March 31, 2024, there was $56.0 million of total unrecognized stock-based compensation expense related to unvested RSUs and stock options, which is expected to be recognized over the remaining weighted-average vesting period of 3.1 years.

Revenue Recognition - Costs to obtain a contract (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Change in the balance of costs to obtain a contract
Balance at beginning of period	$ 288	$ 377
Deferral of costs to obtain a contract	97	197
Amortization of costs to obtain a contract	(95)	(191)
Balance at end of period	290	383
Impairment loss	$ 0	$ 0

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of disaggregated revenue


	Three Months Ended March 31, 2024								Three Months Ended March 31, 2023
	North America		EMEA		Asia Pacific		Total		North America		EMEA		Asia Pacific		Total
	(As Restated)		(As Restated)		(As Restated)				(As Restated)		(As Restated)		(As Restated)		(As Restated)
Product revenue:
Instruments	$	408	$	1,269	$	869	$	2,546	$	2,144	$	1,981	$	1,135	$	5,260
Consumable and other products	10,297		4,299		2,528		17,124		7,497		4,971		1,632		14,100
Total	$	10,705	$	5,568	$	3,397	$	19,670	$	9,641	$	6,952	$	2,767	$	19,360

Service revenue:
Service-type warranties	$	1,637	$	852	$	194	$	2,683	$	1,517	$	675	$	133	$	2,325
Research services	5,762		2,802		127		8,691		5,190		234		115		5,539
Other services	318		248		27		593		381		257		4		642
Total	$	7,717	$	3,902	$	348	$	11,967	$	7,088	$	1,166	$	252	$	8,506

Collaboration and license revenue:
Total	$	155	$	—	$	—	$	155	$	368	$	—	$	—	$	368

Schedule of costs to obtain a contract

Changes in costs to obtain a contract were as follows (in thousands):


	2024		2023
Balance at December 31 of prior year	$	288	$	377
Capitalization of costs to obtain a contract	97		197
Recognition of costs to obtain a contract	(95)		(191)
Balance at March 31	$	290	$	383

Restatement of Financial Statements - Statement Of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (11,163)	$ (7,274)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,523	1,454
Credit losses (gains) on accounts receivable	176	178
Amortization of (discount) premium on marketable securities	(1,657)	0
Operating lease right-of-use asset amortization	478	334
Stock-based compensation expense	5,265	3,943
Other operating activity	55	270
Changes in assets and liabilities:
Accounts receivable	(4,233)	(3,741)
Inventory	(2,531)	530
Prepaid expenses and other current assets	(281)	(422)
Other non-current assets	(33)	(33)
Accounts payable	(1,057)	(1,271)
Accrued compensation and benefits, accrued expenses, and other current liabilities	(6,200)	(5,809)
Deferred revenue	472	2,041
Operating lease liabilities	(988)	179
Other non-current liabilities	10	(203)
Net cash used in operating activities	(20,164)	(9,824)
Cash flows from investing activities:
Purchases of marketable securities	(137,889)	0
Proceeds from maturities of marketable debt securities	29,200	0
Purchases of property and equipment	(506)	(136)
Net cash used in investing activities	(109,195)	(136)
Cash flows from financing activities:
Proceeds from common stock issued under stock plans	2,037	564
Payments for employee taxes withheld on stock-based compensation awards	(1,438)	(13)
Net cash provided by financing activities	599	551
Net increase (decrease) in cash, cash equivalents, and restricted cash	(128,760)	(9,409)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(380)	24
Cash, cash equivalents, and restricted cash at beginning of period	177,026	341,337
Cash, cash equivalents, and restricted cash at end of period	47,886	331,952
Supplemental disclosure of cash flow information:
Cash paid for taxes	175	246
Purchases of property and equipment in accounts payable and accruals	222	147
As Previously Reported
Cash flows from operating activities:
Net loss	(10,072)	(6,103)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,523	1,439
Credit losses (gains) on accounts receivable	176	178
Amortization of (discount) premium on marketable securities	(1,657)
Operating lease right-of-use asset amortization	478	334
Stock-based compensation expense	5,265	3,902
Other operating activity	55	270
Changes in assets and liabilities:
Accounts receivable	(4,233)	(3,741)
Inventory	(3,670)	(89)
Prepaid expenses and other current assets	(254)	(422)
Other non-current assets	(21)	(33)
Accounts payable	(1,122)	(1,271)
Accrued compensation and benefits, accrued expenses, and other current liabilities	(6,126)	(5,983)
Deferred revenue	472	2,041
Operating lease liabilities	(988)	179
Other non-current liabilities	10	(203)
Net cash used in operating activities	(20,164)	(9,502)
Cash flows from investing activities:
Purchases of marketable securities	(137,889)
Proceeds from maturities of marketable debt securities	29,200
Purchases of property and equipment	(506)	(136)
Net cash used in investing activities	(109,195)	(136)
Cash flows from financing activities:
Proceeds from common stock issued under stock plans	2,037	564
Payments for employee taxes withheld on stock-based compensation awards	(1,438)	(13)
Net cash provided by financing activities	599	551
Net increase (decrease) in cash, cash equivalents, and restricted cash	(128,760)	(9,087)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(380)	24
Cash, cash equivalents, and restricted cash at beginning of period	177,026	341,337
Cash, cash equivalents, and restricted cash at end of period	47,886	332,274
Supplemental disclosure of cash flow information:
Cash paid for taxes	175	246
Purchases of property and equipment in accounts payable and accruals	222	147
Adjustments
Cash flows from operating activities:
Net loss	(1,091)	(1,171)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	0	15
Credit losses (gains) on accounts receivable	0	0
Amortization of (discount) premium on marketable securities	0
Operating lease right-of-use asset amortization	0	0
Stock-based compensation expense	0	41
Other operating activity	0	0
Changes in assets and liabilities:
Accounts receivable	0	0
Inventory	1,139	619
Prepaid expenses and other current assets	(27)	0
Other non-current assets	(12)	0
Accounts payable	65	0
Accrued compensation and benefits, accrued expenses, and other current liabilities	(74)	174
Deferred revenue	0	0
Operating lease liabilities	0	0
Other non-current liabilities	0	0
Net cash used in operating activities	0	(322)
Cash flows from investing activities:
Purchases of marketable securities	0
Proceeds from maturities of marketable debt securities	0
Purchases of property and equipment	0	0
Net cash used in investing activities	0	0
Cash flows from financing activities:
Proceeds from common stock issued under stock plans	0	0
Payments for employee taxes withheld on stock-based compensation awards	0	0
Net cash provided by financing activities	0	0
Net increase (decrease) in cash, cash equivalents, and restricted cash	0	(322)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	0	0
Cash, cash equivalents, and restricted cash at beginning of period	0	0
Cash, cash equivalents, and restricted cash at end of period	0	(322)
Supplemental disclosure of cash flow information:
Cash paid for taxes	0	0
Purchases of property and equipment in accounts payable and accruals	$ 0	$ 0

Restatement of Financial Statements (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Changes and Error Corrections [Abstract]

Schedule of Error Corrections and Prior Period Adjustments

QUANTERIX CORPORATION

RESTATED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except per share data)


	As of March 31, 2024
	As Previously Reported		Adjustments		As Restated
ASSETS
Current assets:
Cash and cash equivalents	$	45,281	$	—	$	45,281
Marketable securities	256,640		—		256,640
Accounts receivable, net of allowance for expected credit losses	29,276		—		29,276
Inventory	26,015		2,619		28,634
Prepaid expenses and other current assets	9,551		(30)		9,521
Total current assets	366,763		2,589		369,352
Restricted cash	2,605		—		2,605
Property and equipment, net	17,492		—		17,492
Intangible assets, net	5,339		—		5,339
Operating lease right-of-use assets	17,748		—		17,748
Other non-current assets	1,802		(133)		1,669
Total assets	$	411,749	$	2,456	$	414,205
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	3,914	$	65	$	3,979
Accrued compensation and benefits	6,706		490		7,196
Accrued expenses and other current liabilities	7,021		(39)		6,982
Deferred revenue	10,234		—		10,234
Operating lease liabilities	4,366		—		4,366
Total current liabilities	32,241		516		32,757
Deferred revenue, net of current portion	933		—		933
Operating lease liabilities, net of current portion	36,084		—		36,084
Other non-current liabilities	1,053		—		1,053
Total liabilities	70,311		516		70,827
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.001 par value per share:
Authorized: 120,000 shares; issued and outstanding: 38,288 shares at March 31, 2024	38		—		38
Additional paid-in capital	789,006		—		789,006
Accumulated other comprehensive loss	(3,038)		85		(2,953)
Accumulated deficit	(444,568)		1,855		(442,713)
Total stockholders’ equity	341,438		1,940		343,378
Total liabilities and stockholders’ equity	$	411,749	$	2,456	$	414,205


	As of December 31, 2023
	As Previously Reported		Adjustments		As Restated
ASSETS
Current assets:
Cash and cash equivalents	$	174,422	$	—	$	174,422
Marketable securities	146,902		—		146,902
Accounts receivable, net of allowance for expected credit losses	25,414		—		25,414
Inventory	22,365		3,758		26,123
Prepaid expenses and other current assets	9,291		(57)		9,234
Total current assets	378,394		3,701		382,095
Restricted cash	2,604		—		2,604
Property and equipment, net	17,926		—		17,926
Intangible assets, net	6,034		—		6,034
Operating lease right-of-use assets	18,251		—		18,251
Other non-current assets	1,802		(145)		1,657
Total assets	$	425,011	$	3,556	$	428,567
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	5,048	$	—	$	5,048
Accrued compensation and benefits	13,659		511		14,170
Accrued expenses and other current liabilities	6,041		14		6,055
Deferred revenue	9,468		—		9,468
Operating lease liabilities	4,241		—		4,241
Total current liabilities	38,457		525		38,982
Deferred revenue, net of current portion	1,227		—		1,227
Operating lease liabilities, net of current portion	37,223		—		37,223
Other non-current liabilities	1,177		—		1,177
Total liabilities	78,084		525		78,609
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.001 par value per share:
Authorized: 120,000 shares; issued and outstanding: 38,014 shares at December 31, 2023	38		—		38
Additional paid-in capital	783,142		—		783,142
Accumulated other comprehensive loss	(1,757)		85		(1,672)
Accumulated deficit	(434,496)		2,946		(431,550)
Total stockholders’ equity	346,927		3,031		349,958
Total liabilities and stockholders’ equity	$	425,011	$	3,556	$	428,567

QUANTERIX CORPORATION

RESTATED CONSOLIDATED STATEMENTS OF OPERATIONS

(amounts in thousands, except per share data)


	Three Months Ended March 31, 2024						Three Months Ended March 31, 2023
	As Previously Reported		Adjustments		As Restated		As Previously Reported		Adjustments		As Restated
Revenues:
Product revenue	$	19,670	$	—	$	19,670	$	19,287	$	73	$	19,360
Service revenue	11,967		—		11,967		8,579		(73)		8,506
Collaboration and license revenue	155		—		155		368		—		368
Grant revenue	274		—		274		222		—		222
Total revenues	32,066		—		32,066		28,456		—		28,456
Costs of goods sold and services:
Cost of product revenue	7,145		1,092		8,237		7,033		846		7,879
Cost of service and other revenue	5,295		(14)		5,281		4,497		87		4,584
Total costs of goods sold and services	12,440		1,078		13,518		11,530		933		12,463
Gross profit	19,626		(1,078)		18,548		16,926		(933)		15,993
Operating expenses:
Research and development	6,675		67		6,742		4,720		267		4,987
Selling, general, and administrative	25,993		46		26,039		20,850		(66)		20,784
Other lease costs	924		—		924		776		24		800
Total operating expenses	33,592		113		33,705		26,346		225		26,571
Loss from operations	(13,966)		(1,191)		(15,157)		(9,420)		(1,158)		(10,578)
Interest income	3,948		—		3,948		3,449		—		3,449
Other income (expense), net	206		20		226		8		(13)		(5)
Loss before income taxes	(9,812)		(1,171)		(10,983)		(5,963)		(1,171)		(7,134)
Income tax expense	(260)		80		(180)		(140)		—		(140)
Net loss	$	(10,072)	$	(1,091)	$	(11,163)	$	(6,103)	$	(1,171)	$	(7,274)

Net loss per common share, basic and diluted	$	(0.26)	$	(0.03)	$	(0.29)	$	(0.16)	$	(0.03)	$	(0.19)

Weighted-average common shares outstanding, basic and diluted	38,126		—		38,126		37,327		—		37,327

QUANTERIX CORPORATION

RESTATED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(amounts in thousands)


	Three Months Ended March 31, 2024						Three Months Ended March 31, 2023
	As Previously Reported		Adjustments		As Restated		As Previously Reported		Adjustments		As Restated
Net loss	$	(10,072)	$	(1,091)	$	(11,163)	$	(6,103)	$	(1,171)	$	(7,274)
Other comprehensive income (loss), net of tax:
Unrealized losses on marketable securities	(607)		—		(607)		—		—		—
Foreign currency translation adjustment	(674)		—		(674)		42		—		42
Total other comprehensive income (loss)	(1,281)		—		(1,281)		42		—		42
Comprehensive loss	$	(11,353)	$	(1,091)	$	(12,444)	$	(6,061)	$	(1,171)	$	(7,232)

QUANTERIX CORPORATION

RESTATED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(amounts in thousands)


	Three Months Ended March 31, 2024
	Common Stock
As Previously Reported	Shares	Amount		Additional paid-in capital		Accumulated other comprehensive income (loss)		Accumulated deficit		Total stockholders' equity
Balance at December 31, 2023	38,014	$	38	$	783,142	$	(1,757)	$	(434,496)	$	346,927
Issuance of common stock under stock plans, including tax effects	274	—		599		—		—		599
Stock-based compensation expense	—	—		5,265		—		—		5,265
Unrealized loss on marketable securities, net of tax	—	—		—		(607)		—		(607)
Foreign currency translation adjustment	—	—		—		(674)		—		(674)
Net loss	—	—		—		—		(10,072)		(10,072)
Balance at March 31, 2024	38,288	$	38	$	789,006	$	(3,038)	$	(444,568)	$	341,438

Adjustments
Balance at December 31, 2023	—	$	—	$	—	$	85	$	2,946	$	3,031
Issuance of common stock under stock plans, including tax effects	—	—		—		—		—		—
Stock-based compensation expense	—	—		—		—		—		—
Unrealized loss on marketable securities, net of tax	—	—		—		—		—		—
Foreign currency translation adjustment	—	—		—		—		—		—
Net loss	—	—		—		—		(1,091)		(1,091)
Balance at March 31, 2024	—	$	—	$	—	$	85	$	1,855	$	1,940
As Restated
Balance at December 31, 2023	38,014	$	38	$	783,142	$	(1,672)	$	(431,550)	$	349,958
Issuance of common stock under stock plans, including tax effects	274	—		599		—		—		599
Stock-based compensation expense	—	—		5,265		—		—		5,265
Unrealized loss on marketable securities, net of tax	—	—		—		(607)		—		(607)
Foreign currency translation adjustment	—	—		—		(674)		—		(674)
Net loss	—	—		—		—		(11,163)		(11,163)
Balance at March 31, 2024	38,288	$	38	$	789,006	$	(2,953)	$	(442,713)	$	343,378


	Three Months Ended March 31, 2023
	Common Stock
As Previously Reported	Shares	Amount		Additional paid-in capital		Accumulated other comprehensive income (loss)		Accumulated deficit		Total stockholders' equity
Balance at December 31, 2022	37,280	$	37	$	763,688	$	(2,623)	$	(402,162)	$	358,940
Issuance of common stock under stock plans, including tax effects	144	—		551		—		—		551
Stock-based compensation expense	—	—		3,902		—		—		3,902
Foreign currency translation adjustment	—	—		—		42		—		42
Net loss	—	—		—		—		(6,103)		(6,103)
Balance at March 31, 2023	37,424	$	37	$	768,141	$	(2,581)	$	(408,265)	$	357,332
Adjustments
Balance at December 31, 2022	—	$	—	$	(59)	$	85	$	(1,034)	$	(1,008)
Issuance of common stock under stock plans, including tax effects	—	—		—		—		—		—
Stock-based compensation expense	—	—		41		—		—		41
Foreign currency translation adjustment	—	—		—		—		—		—
Net loss	—	—		—		—		(1,171)		(1,171)
Balance at March 31, 2023	—	$	—	$	(18)	$	85	$	(2,205)	$	(2,138)
As Restated
Balance at December 31, 2022	37,280	$	37	$	763,629	$	(2,538)	$	(403,196)	$	357,932
Issuance of common stock under stock plans, including tax effects	144	—		551		—		—		551
Stock-based compensation expense	—	—		3,943		—		—		3,943
Foreign currency translation adjustment	—	—		—		42		—		42
Net loss	—	—		—		—		(7,274)		(7,274)
Balance at March 31, 2023	37,424	$	37	$	768,123	$	(2,496)	$	(410,470)	$	355,194

QUANTERIX CORPORATION

RESTATED CONSOLIDATED STATEMENTS OF CASH FLOWS

(amounts in thousands)


	Three Months Ended, March 31, 2024
	As Previously Reported		Adjustments		As Restated
Cash flows from operating activities:
Net loss	$	(10,072)	$	(1,091)	$	(11,163)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,523		—		1,523
Credit losses on accounts receivable	176		—		176
Accretion of marketable securities	(1,657)		—		(1,657)
Operating lease right-of-use asset amortization	478		—		478
Stock-based compensation expense	5,265		—		5,265
Other operating activity	55		—		55
Changes in assets and liabilities:
Accounts receivable	(4,233)		—		(4,233)
Inventory	(3,670)		1,139		(2,531)
Prepaid expenses and other current assets	(254)		(27)		(281)
Other non-current assets	(21)		(12)		(33)
Accounts payable	(1,122)		65		(1,057)
Accrued compensation and benefits, accrued expenses, and other current liabilities	(6,126)		(74)		(6,200)
Deferred revenue	472		—		472
Operating lease liabilities	(988)		—		(988)
Other non-current liabilities	10		—		10
Net cash used in operating activities	(20,164)		—		(20,164)
Cash flows from investing activities:
Purchases of marketable securities	(137,889)		—		(137,889)
Proceeds from maturities of marketable securities	29,200		—		29,200
Purchases of property and equipment	(506)		—		(506)
Net cash used in investing activities	(109,195)		—		(109,195)
Cash flows from financing activities:
Proceeds from common stock issued under stock plans	2,037		—		2,037
Payments for employee taxes withheld on stock-based compensation awards	(1,438)		—		(1,438)
Net cash provided by financing activities	599		—		599
Net decrease in cash, cash equivalents, and restricted cash	(128,760)		—		(128,760)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(380)		—		(380)
Cash, cash equivalents, and restricted cash at beginning of period	177,026		—		177,026
Cash, cash equivalents, and restricted cash at end of period	$	47,886	$	—	$	47,886

Supplemental disclosure of cash flow information:
Cash paid for taxes	$	175	$	—	$	175
Purchases of property and equipment in accounts payable and accruals	$	222	$	—	$	222


	Three Months Ended, March 31, 2023
	As Previously Reported		Adjustments		As Restated
Cash flows from operating activities:
Net loss	$	(6,103)	$	(1,171)	$	(7,274)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,439		15		1,454
Credit losses on accounts receivable	178		—		178
Operating lease right-of-use asset amortization	334		—		334
Stock-based compensation expense	3,902		41		3,943
Other operating activity	270		—		270
Changes in assets and liabilities:
Accounts receivable	(3,741)		—		(3,741)
Inventory	(89)		619		530
Prepaid expenses and other current assets	(422)		—		(422)
Other non-current assets	(33)		—		(33)
Accounts payable	(1,271)		—		(1,271)
Accrued compensation and benefits, accrued expenses, and other current liabilities	(5,983)		174		(5,809)
Deferred revenue	2,041		—		2,041
Operating lease liabilities	179		—		179
Other non-current liabilities	(203)		—		(203)
Net cash used in operating activities	(9,502)		(322)		(9,824)
Cash flows from investing activities:
Purchases of property and equipment	(136)		—		(136)
Net cash used in investing activities	(136)		—		(136)
Cash flows from financing activities:
Proceeds from common stock issued under stock plans	564		—		564
Payments for employee taxes withheld on stock-based compensation awards	(13)		—		(13)
Net cash provided by financing activities	551		—		551
Net decrease in cash, cash equivalents, and restricted cash	(9,087)		(322)		(9,409)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	24		—		24
Cash, cash equivalents, and restricted cash at beginning of period	341,337		—		341,337
Cash, cash equivalents, and restricted cash at end of period	$	332,274	$	(322)	$	331,952

Supplemental disclosure of cash flow information:
Cash paid for taxes	$	246	$	—	$	246
Purchases of property and equipment in accounts payable and accruals	$	147	$	—	$	147

Allowance for Credit Losses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Allowance for Credit Loss [Abstract]
Beginning Balance	$ 454	$ 118
Provision for expected credit losses	176	178
Write-offs and recoveries collected	(103)	(74)
Ending Balance	$ 527	$ 222

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw Materials	$ 6,082	$ 5,114
Work in process	8,391	5,439
Finished goods	14,161	15,570
Total inventory	$ 28,634	$ 26,123

Net Income (Loss) Per Share

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Net Loss Per Share

Note 11. Net Loss Per Share

The following table presents the computation of basic and diluted net loss per share (in thousands, except per share data):


	Three Months Ended March 31,
	2024		2023
	(As Restated)		(As Restated)
Numerator:
Net loss	$	(11,163)	$	(7,274)
Denominator:
Weighted average common shares outstanding, basic and diluted	38,126		37,327

Net loss per share, basic and diluted	$	(0.29)	$	(0.19)

As the Company was in a net loss position for all periods listed in the table below, the following common share equivalents (calculated on a weighted average basis) were excluded from the calculation of diluted net loss per share (in thousands):


	Three Months Ended March 31,
	2024	2023
Stock options	3,520	2,720
Common stock and RSUs	1,497	1,489
Estimated ESPP purchases	19	26
Total dilutive shares	5,036	4,235

Commitments and Contingencies - License agreements and Lease commitments (Details) - License agreements - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Aug. 31, 2022	Mar. 31, 2024	Mar. 31, 2023
License agreements
Royalty expense		$ 0.0	$ 0.0
Tufts
License agreements
Royalty expense		$ 0.5	$ 0.4
Harvard University
License agreements
Upfront Fee	$ 0.6

Revenue Recognition - Service Revenue (Details) $ in Thousands	3 Months Ended		12 Months Ended	15 Months Ended
	Mar. 31, 2024 USD ($) customer	Mar. 31, 2023 USD ($) customer	Dec. 31, 2023 USD ($)	Mar. 31, 2024 USD ($) customer
Service Revenue
Revenue	$ 32,066	$ 28,456
Customer Concentration Risk [Member] \| Revenue Benchmark [Member]
Service Revenue
Number Of Customers With High Percent Of Total Revenue \| customer	0
Concentration Risk Percentage	10.00%			10.00%
One customer \| Customer Concentration Risk [Member] \| Revenue Benchmark [Member]
Service Revenue
Number Of Customers With High Percent Of Total Revenue \| customer		1
Concentration Risk Percentage		10.00%
One customer \| Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Service Revenue
Number Of Customers With High Percent Of Gross Accounts Receivable \| customer	1			1
Concentration Risk Percentage	10.00%			10.00%
Service revenue
Service Revenue
Revenue	$ 11,967	$ 8,506
Collaboration agreement \| Eli Lilly
Service Revenue
Revenue		$ 1,500		$ 1,500
Statement of works agreement \| Eli Lilly
Service Revenue
Collaborative arrangement payment received per quarter			$ 1,500

Stock-Based Compensation - Stock options (Details) - Employee Stock Option - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Number outstanding
Outstanding at the beginning of the period (in shares)	2,774
Granted (in shares)	1,179
Exercised (in shares)	(104)
Cancelled (in shares)	(181)
Outstanding at the end of the period (in shares)	3,668	2,774
Exercisable at the end of the period (in shares)	1,297
Vested and expected to vest at the end of the period (in shares)	3,668
Weighted-average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 19.62
Granted (in dollars per share)	22.74
Exercised (in dollars per share)	12.34
Cancelled (in dollars per share)	20.24
Outstanding at the end of the period (in dollars per share)	20.80	$ 19.62
Exercisable at the end of the period (in dollars per share)	22.24
Vested and expected to vest at the end of the period (in dollars per share)	$ 20.80
Weighted-average remaining contractual life
Outstanding (in years)	8 years 3 months 18 days	7 years 10 months 24 days
Exercisable at the end of the period (in years)	6 years 7 months 6 days
Vested and expected to vest at the end of the period (in years)	8 years 3 months 18 days
Aggregate intrinsic value
Outstanding	$ 17,741	$ 26,941
Exercisable at the end of the period	7,615
Vested and expected to vest at the end of the period	$ 17,741

Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Schedule of restricted cash and cash equivalents


	As of March 31,
	2024		2023
			(As Restated)
Cash and cash equivalents	$	45,281	$	329,354
Restricted cash	2,605		2,598
Cash, cash equivalents, and restricted cash	$	47,886	$	331,952

Stock-Based Compensation - Share-based compensation expense (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stock-based compensation
Share-based compensation expense	$ 5,265	$ 3,943
2017 ESPP
Stock-based compensation
Stock issued during period, shares, employee stock purchase plans	36
Cost of product revenue
Stock-based compensation
Share-based compensation expense	$ 281	197
Cost of service and other revenue
Stock-based compensation
Share-based compensation expense	308	350
Research and development
Stock-based compensation
Share-based compensation expense	543	379
General and Administrative Expense
Stock-based compensation
Share-based compensation expense	4,133	$ 3,017
Restricted stock units and stock options
Stock-based compensation
Total unrecognized compensation cost related to unvested stock awards	$ 56,000
Period of recognition of unrecognized compensation cost	3 years 1 month 6 days

Net Income (Loss) Per Share - Basic and diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Net loss	$ (11,163)	$ (7,274)
Weighted-average common shares outstanding, basic (in shares)	38,126,000	37,327,000
Weighted-average common shares outstanding, diluted (in shares)	38,126,000	37,327,000
Basic net (loss) income per share	$ (0.29)	$ (0.19)
Diluted net (loss) income per share	$ (0.29)	$ (0.19)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Revenue Recognition - Collaboration and license arrangements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Collaboration and license arrangements
Revenue	$ 32,066	$ 28,456
Collaboration and license revenue
Collaboration and license arrangements
Revenue	$ 155	$ 368

- Definition

+ References

+ Details

Accrued Expenses and Other Current Liabilities (Tables)

3 Months Ended

Mar. 31, 2024

Accrued Expenses and Other Current Liabilities

Summary of Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31, 2024		December 31, 2023
	(As Restated)		(As Restated)
Accrued professional services	$	1,947	$	1,596
Accrued royalties	1,631		1,689
Accrued tax liabilities	1,446		822
Other accrued expenses	1,958		1,948
Total accrued expenses and other current liabilities	$	6,982	$	6,055

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (11,163)	$ (7,274)
Other comprehensive loss, net of tax:
Unrealized gains on marketable securities	(607)	0
Foreign currency translation adjustment	(674)	42
Total other comprehensive loss	(1,281)	42
Comprehensive loss	$ (12,444)	$ (7,232)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Organization and Nature of Business (Details)	Mar. 31, 2024 project customer
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of projects completed \| project	2,300
Entity number of customers served \| customer	480

Stock-Based Compensation - Restricted stock units (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Number of restricted stock units
Unvested restricted common stock at the beginning of the period (in shares) \| shares	1,328
Granted (in shares) \| shares	446
Vested (in shares) \| shares	(197)
Cancelled (in shares) \| shares	(96)
Unvested restricted common stock at the end of the period (in shares) \| shares	1,481
Weighted-average grant date fair value per share
Unvested restricted common stock at the beginning of the period (in dollars per share) \| $ / shares	$ 17.87
Granted (in dollars per share) \| $ / shares	24.40
Vested (in dollars per share) \| $ / shares	17.57
Cancelled (in dollars per share) \| $ / shares	20.52
Unvested restricted common stock at the end of the period (in dollars per share) \| $ / shares	$ 19.71

Restatement of Financial Statements - Statement Of Stockholders' Equity (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Reclassification [Line Items]
Beginning Balance	$ 349,958	$ 357,932
Issuance of common stock under stock plans, including tax effects	599	551
Stock-based compensation expense	5,265	3,943
Unrealized loss on marketable securities, net of tax	(607)	0
Foreign currency translation adjustment	(674)	42
Net loss	(11,163)	(7,274)
Ending Balance	$ 343,378	$ 355,194
Common Stock
Reclassification [Line Items]
Beginning balance (in shares)	38,014	37,280
Beginning Balance	$ 38	$ 37
Issuance of common stock under stock plans, including tax effects (in shares)	274	144
Ending Balance (in shares)	38,288	37,424
Ending Balance	$ 38	$ 37
Additional paid-in capital
Reclassification [Line Items]
Beginning Balance	783,142	763,629
Issuance of common stock under stock plans, including tax effects	599	551
Stock-based compensation expense	5,265	3,943
Ending Balance	789,006	768,123
Accumulated other comprehensive income (loss)
Reclassification [Line Items]
Beginning Balance	(1,672)	(2,538)
Unrealized loss on marketable securities, net of tax	(607)
Foreign currency translation adjustment	(674)	42
Ending Balance	(2,953)	(2,496)
Accumulated deficit
Reclassification [Line Items]
Beginning Balance	(431,550)	(403,196)
Net loss	(11,163)	(7,274)
Ending Balance	(442,713)	(410,470)
As Previously Reported
Reclassification [Line Items]
Beginning Balance	346,927	358,940
Issuance of common stock under stock plans, including tax effects	599	551
Stock-based compensation expense	5,265	3,902
Unrealized loss on marketable securities, net of tax	(607)	0
Foreign currency translation adjustment	(674)	42
Net loss	(10,072)	(6,103)
Ending Balance	$ 341,438	$ 357,332
As Previously Reported \| Common Stock
Reclassification [Line Items]
Beginning balance (in shares)	38,014	37,280
Beginning Balance	$ 38	$ 37
Issuance of common stock under stock plans, including tax effects (in shares)	274	144
Ending Balance (in shares)	38,288	37,424
Ending Balance	$ 38	$ 37
As Previously Reported \| Additional paid-in capital
Reclassification [Line Items]
Beginning Balance	783,142	763,688
Issuance of common stock under stock plans, including tax effects	599	551
Stock-based compensation expense	5,265	3,902
Ending Balance	789,006	768,141
As Previously Reported \| Accumulated other comprehensive income (loss)
Reclassification [Line Items]
Beginning Balance	(1,757)	(2,623)
Unrealized loss on marketable securities, net of tax	(607)
Foreign currency translation adjustment	(674)	42
Ending Balance	(3,038)	(2,581)
As Previously Reported \| Accumulated deficit
Reclassification [Line Items]
Beginning Balance	(434,496)	(402,162)
Net loss	(10,072)	(6,103)
Ending Balance	(444,568)	(408,265)
Adjustments
Reclassification [Line Items]
Beginning Balance	3,031	(1,008)
Stock-based compensation expense		41
Unrealized loss on marketable securities, net of tax	0	0
Foreign currency translation adjustment	0	0
Net loss	(1,091)	(1,171)
Ending Balance	$ 1,940	$ (2,138)
Adjustments \| Common Stock
Reclassification [Line Items]
Beginning balance (in shares)	0	0
Beginning Balance	$ 0	$ 0
Ending Balance (in shares)	0	0
Ending Balance	$ 0	$ 0
Adjustments \| Additional paid-in capital
Reclassification [Line Items]
Beginning Balance	0	(59)
Stock-based compensation expense		41
Ending Balance	0	(18)
Adjustments \| Accumulated other comprehensive income (loss)
Reclassification [Line Items]
Beginning Balance	85	85
Ending Balance	85	85
Adjustments \| Accumulated deficit
Reclassification [Line Items]
Beginning Balance	2,946	(1,034)
Net loss	(1,091)	(1,171)
Ending Balance	$ 1,855	$ (2,205)

Net Income (Loss) Per Share (Tables)

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following table presents the computation of basic and diluted net loss per share (in thousands, except per share data):


	Three Months Ended March 31,
	2024		2023
	(As Restated)		(As Restated)
Numerator:
Net loss	$	(11,163)	$	(7,274)
Denominator:
Weighted average common shares outstanding, basic and diluted	38,126		37,327

Net loss per share, basic and diluted	$	(0.29)	$	(0.19)

Schedule of common share equivalents have been excluded from the calculation of diluted net loss per share


	Three Months Ended March 31,
	2024	2023
Stock options	3,520	2,720
Common stock and RSUs	1,497	1,489
Estimated ESPP purchases	19	26
Total dilutive shares	5,036	4,235

Revenue Recognition - Disaggregated revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Service Revenue
Total revenues	$ 32,066	$ 28,456
Product revenue
Service Revenue
Total revenues	19,670	19,360
Product revenue \| North America
Service Revenue
Total revenues	10,705	9,641
Product revenue \| EMEA
Service Revenue
Total revenues	5,568	6,952
Product revenue \| Asia Pacific
Service Revenue
Total revenues	3,397	2,767
Instruments
Service Revenue
Total revenues	2,546	5,260
Instruments \| North America
Service Revenue
Total revenues	408	2,144
Instruments \| EMEA
Service Revenue
Total revenues	1,269	1,981
Instruments \| Asia Pacific
Service Revenue
Total revenues	869	1,135
Consumable and other products
Service Revenue
Total revenues	17,124	14,100
Consumable and other products \| North America
Service Revenue
Total revenues	10,297	7,497
Consumable and other products \| EMEA
Service Revenue
Total revenues	4,299	4,971
Consumable and other products \| Asia Pacific
Service Revenue
Total revenues	2,528	1,632
Service revenue
Service Revenue
Total revenues	11,967	8,506
Service revenue \| North America
Service Revenue
Total revenues	7,717	7,088
Service revenue \| EMEA
Service Revenue
Total revenues	3,902	1,166
Service revenue \| Asia Pacific
Service Revenue
Total revenues	348	252
Research services
Service Revenue
Total revenues	8,691	5,539
Research services \| North America
Service Revenue
Total revenues	5,762	5,190
Research services \| EMEA
Service Revenue
Total revenues	2,802	234
Research services \| Asia Pacific
Service Revenue
Total revenues	127	115
Other services
Service Revenue
Total revenues	593	642
Other services \| North America
Service Revenue
Total revenues	318	381
Other services \| EMEA
Service Revenue
Total revenues	248	257
Other services \| Asia Pacific
Service Revenue
Total revenues	27	4
Service-type warranties
Service Revenue
Total revenues	2,683	2,325
Service-type warranties \| North America
Service Revenue
Total revenues	1,637	1,517
Service-type warranties \| EMEA
Service Revenue
Total revenues	852	675
Service-type warranties \| Asia Pacific
Service Revenue
Total revenues	194	133
Collaboration and license revenue
Service Revenue
Total revenues	155	368
Collaboration and license revenue \| North America
Service Revenue
Total revenues	155	368
Collaboration and license revenue \| EMEA
Service Revenue
Total revenues	0	0
Collaboration and license revenue \| Asia Pacific
Service Revenue
Total revenues	0	0
Grant revenue
Service Revenue
Total revenues	274	222
Service revenue
Service Revenue
Total revenues	$ 11,967	$ 8,506

Revenue Recognition - Remaining Performance Obligations (Details) $ in Millions	Mar. 31, 2024 USD ($)
Transaction Price Allocated to Remaining Performance Obligations
Amount of transaction price allocated to performance obligations	$ 11.2
Undelivered licenses of intellectual property
Transaction Price Allocated to Remaining Performance Obligations
Amount of transaction price allocated to performance obligations	11.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01
Transaction Price Allocated to Remaining Performance Obligations
Amount of transaction price allocated to performance obligations	$ 10.2
Performance obligation satisfaction period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01
Transaction Price Allocated to Remaining Performance Obligations
Amount of transaction price allocated to performance obligations	$ 1.0
Performance obligation satisfaction period	15 months

Allowance for Credit Losses

3 Months Ended

Mar. 31, 2024

Allowance for Credit Loss [Abstract]

Allowance for Credit Losses

Note 5. Allowance for Credit Losses

The change in the allowance for expected credit losses on accounts receivable is summarized as follows (in thousands):


	2024		2023
Balance at December 31 of prior year	$	454	$	118
Provision for expected credit losses	176		178
Write-offs and recoveries collected	(103)		(74)
Balance at March 31	$	527	$	222

Commitments and Contingencies - Purchase Commitments (Details) item in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024 USD ($) item	Mar. 31, 2023 USD ($) item	Dec. 31, 2024 USD ($) item
Commitments and contingencies
Tenant improvements allowances		$ 900
Cost of revenue	$ 13,518	12,463
Accounts payable	$ (1,057)	$ (1,271)
Stratec Supply Agreement
Commitments and contingencies
Number of discs shipped \| item	35	75
Purchase commitments expects to incur in next year	$ 1,600
Other Commitment	3,700
Cost of revenue	300	$ 500
Accounts payable	$ 2,100
Stratec Supply Agreement \| Forecast
Commitments and contingencies
Number of discs shipped \| item			222
Purchase commitments expects to incur in next year			$ 3,800
Stratec Supply Agreement \| Forecast 2022 Through 2024
Commitments and contingencies
Number of discs purchased \| item	515

Inventory

3 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

Inventory

Note 8. Inventory

Inventory, net of inventory reserves, consisted of the following (in thousands):


	March 31, 2024		December 31, 2023
	(As Restated)		(As Restated)
Raw materials	$	6,082	$	5,114
Work in process	8,391		5,439
Finished goods	14,161		15,570
Total inventory	$	28,634	$	26,123

Marketable Securities

3 Months Ended

Mar. 31, 2024

Investments, Debt and Equity Securities [Abstract]

Marketable Securities

Note 6. Marketable Securities

The amortized cost, gross unrealized gains, gross unrealized losses, and fair value of the Company’s marketable securities by major security type were as follows (in thousands):


	As of March 31, 2024
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper	$	42,947	$	—	$	(40)	$	42,907
U.S. Treasuries	73,033		—		(23)		73,010
U.S. Government agency bonds	78,389		10		(149)		78,250
Corporate bonds	79,012		55		(136)		78,931
Total marketable securities	$	273,381	$	65	$	(348)	$	273,098

Marketable securities are recorded in the following Consolidated Balance Sheets captions:
Cash and cash equivalents							$	16,458
Marketable securities							256,640
Total marketable securities							$	273,098


	As of December 31, 2023
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper	$	53,482	$	23	$	(12)	$	53,493
U.S. Treasuries	4,896		1		—		4,897
U.S. Government agency bonds	28,366		39		(7)		28,398
Corporate bonds	66,726		289		(8)		67,007
Total marketable securities	$	153,470	$	352	$	(27)	$	153,795

Marketable securities are recorded in the following Consolidated Balance Sheets captions:
Cash and cash equivalents							$	6,893
Marketable securities							146,902
Total marketable securities							$	153,795


	Less Than 12 Months
As of March 31, 2024	Fair Value		Unrealized Losses
Commercial paper	$	38,497	$	(40)
U.S. Treasuries	73,010		(23)
U.S. Government agency bonds	69,825		(149)
Corporate bonds	48,629		(136)
Total	$	229,961	$	(348)


	Less Than 12 Months
As of December 31, 2023	Fair Value		Unrealized Losses
Commercial paper	$	32,137	$	(12)
U.S. Government agency bonds	15,861		(7)
Corporate bonds	8,367		(8)
Total	$	56,365	$	(27)

The Company did not have any individual securities in a continuous loss position for greater than 12 months, and there were no individual securities that were in a significant unrealized loss position as of March 31, 2024. For marketable securities in an unrealized loss position, the Company does not intend to sell them before recovery of their amortized cost bases, it is not more likely than not that the Company will be required to sell them before recovery of their amortized cost bases, and the unrealized losses are not credit related. Accordingly, the Company has not recorded any impairment losses or a credit loss allowance.

The Company did not sell any marketable securities or record any realized gains or losses for the three months ended March 31, 2024. At March 31, 2024 and December 31, 2023, the Company had $1.2 million and $1.0 million, respectively, of accrued interest receivable on its marketable securities, which was recorded in prepaid expenses and other current assets on the Consolidated Balance Sheets.

The following table summarizes the contractual maturities of the Company’s marketable securities (in thousands):


	As of March 31, 2024				As of December 31, 2023
	Amortized Cost		Fair Value		Amortized Cost		Fair Value
Due within one year	$	209,554	$	209,378	$	95,188	$	95,232
Due in one to two years	63,827		63,720		58,282		58,563
Total	$	273,381	$	273,098	$	153,470	$	153,795

Restatement of Financial Statements - Balance Sheet (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 45,281	$ 174,422	$ 329,354
Marketable securities	256,640	146,902
Accounts receivable, net of allowance for expected credit losses	29,276	25,414
Inventory	28,634	26,123
Prepaid expenses and other current assets	9,521	9,234
Total current assets	369,352	382,095
Restricted cash	2,605	2,604
Property and equipment, net	17,492	17,926
Intangible assets, net	5,339	6,034
Operating lease ROU assets	17,748	18,251
Other non-current assets	1,669	1,657
Total assets	414,205	428,567
Current liabilities:
Accounts payable	3,979	5,048
Accrued compensation and benefits	7,196	14,170
Accrued expenses and other current liabilities	6,982	6,055
Deferred revenue	10,234	9,468
Short-term operating lease liabilities	4,366	4,241
Total current liabilities	32,757	38,982
Deferred revenue, net of current portion	933	1,227
Non-current operating lease liabilities	36,084	37,223
Other non-current liabilities	1,053	1,177
Total liabilities	70,827	78,609
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, $0.001 par value, per share: Authorized: XXX,XXX; issued and outstanding: 38,014 and 37,280 shares at December 31, 2023 and 2022, respectively	38	38
Additional paid-in capital	789,006	783,142
Accumulated other comprehensive loss	(2,953)	(1,672)
Accumulated deficit	(442,713)	(431,550)
Total stockholders' equity	343,378	349,958	355,194	$ 357,932
Total liabilities and stockholders' equity	414,205	428,567
As Previously Reported
Current assets:
Cash and cash equivalents	45,281	174,422
Marketable securities	256,640	146,902
Accounts receivable, net of allowance for expected credit losses	29,276	25,414
Inventory	26,015	22,365
Prepaid expenses and other current assets	9,551	9,291
Total current assets	366,763	378,394
Restricted cash	2,605	2,604
Property and equipment, net	17,492	17,926
Intangible assets, net	5,339	6,034
Operating lease ROU assets	17,748	18,251
Other non-current assets	1,802	1,802
Total assets	411,749	425,011
Current liabilities:
Accounts payable	3,914	5,048
Accrued compensation and benefits	6,706	13,659
Accrued expenses and other current liabilities	7,021	6,041
Deferred revenue	10,234	9,468
Short-term operating lease liabilities	4,366	4,241
Total current liabilities	32,241	38,457
Deferred revenue, net of current portion	933	1,227
Non-current operating lease liabilities	36,084	37,223
Other non-current liabilities	1,053	1,177
Total liabilities	70,311	78,084
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, $0.001 par value, per share: Authorized: XXX,XXX; issued and outstanding: 38,014 and 37,280 shares at December 31, 2023 and 2022, respectively	38	38
Additional paid-in capital	789,006	783,142
Accumulated other comprehensive loss	(3,038)	(1,757)
Accumulated deficit	(444,568)	(434,496)
Total stockholders' equity	341,438	346,927	357,332	358,940
Total liabilities and stockholders' equity	411,749	425,011
Adjustments
Current assets:
Cash and cash equivalents	0	0
Marketable securities	0	0
Accounts receivable, net of allowance for expected credit losses	0	0
Inventory	2,619	3,758
Prepaid expenses and other current assets	(30)	(57)
Total current assets	2,589	3,701
Restricted cash	0	0
Property and equipment, net	0	0
Intangible assets, net	0	0
Operating lease ROU assets	0	0
Other non-current assets	(133)	(145)
Total assets	2,456	3,556
Current liabilities:
Accounts payable	65	0
Accrued compensation and benefits	490	511
Accrued expenses and other current liabilities	(39)	14
Deferred revenue	0	0
Short-term operating lease liabilities	0	0
Total current liabilities	516	525
Deferred revenue, net of current portion	0	0
Non-current operating lease liabilities	0	0
Other non-current liabilities	0	0
Total liabilities	516	525
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, $0.001 par value, per share: Authorized: XXX,XXX; issued and outstanding: 38,014 and 37,280 shares at December 31, 2023 and 2022, respectively	0	0
Additional paid-in capital	0	0
Accumulated other comprehensive loss	85	85
Accumulated deficit	1,855	2,946
Total stockholders' equity	1,940	3,031	$ (2,138)	$ (1,008)
Total liabilities and stockholders' equity	$ 2,456	$ 3,556

Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Accounting Policies [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 45,281	$ 174,422	$ 329,354

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Basis of Presentation

The Company’s fiscal year is the twelve-month period from January 1 through December 31, and all references to “2024,” “2023,” and the like refer to the fiscal year unless otherwise noted.

Use of Estimates

Principles of Consolidation

Foreign Currency

Foreign currency transaction gains (losses) are included in other income, net on the Consolidated Statements of Operations and were not material for the three months ended March 31, 2024 and 2023.

Restricted Cash


	As of March 31,
	2024		2023
			(As Restated)
Cash and cash equivalents	$	45,281	$	329,354
Restricted cash	2,605		2,598
Cash, cash equivalents, and restricted cash	$	47,886	$	331,952

Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Recent Accounting Standards to be Adopted

Net Income (Loss) Per Share - Common share equivalents have been excluded from the calculation of diluted net loss per share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net loss per share
Number of common share equivalents excluded in the calculation of diluted net loss per share	5,036	4,235
Employee Stock Option
Net loss per share
Number of common share equivalents excluded in the calculation of diluted net loss per share	3,520	2,720
Common stock and RSUs
Net loss per share
Number of common share equivalents excluded in the calculation of diluted net loss per share	1,497	1,489
Estimated ESPP purchases
Net loss per share
Number of common share equivalents excluded in the calculation of diluted net loss per share	19	26

Restatement of Financial Statements - Balance Sheet (Parenthetical) (Details) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Accounting Changes and Error Corrections [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	38,288,000	38,014,000
Common stock, shares outstanding (in shares)	38,288,000	38,014,000